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Abstract
In Duchenne muscular dystrophy (DMD), angiogenesis appears to be attenuated. Local
administration of angiopoietin 1 (Ang1) has been shown to reduce inflammation, ischemia,
and fibrosis in DMD mice. Ang1 is a vital vascular stabilizing factor that activates the
endothelial cell receptor Tie2, leading to downstream pro-survival PI3K/Akt pathway
activation and eNOS phosphorylation. In this study, we aim to characterize the Ang/Tie2
signaling pathway within the skeletal muscle of mouse models of DMD. Utilizing
immunoblots and RT-qPCR, we show that Ang1 is downregulated, while the antagonist
angiopoietin 2 (Ang2) is upregulated, leading to a decreased Ang1/Ang2 ratio. This
correlates with a reduction in phosphorylated Tie2/total Tie2 ratio. Interestingly, no
significant differences in Akt or eNOS phosphorylation were observed, although DMD
murine models did have elevated total Akt protein concentrations. These observations
suggest

that Ang1/Tie2 signaling may be dysregulated in

DMD and further

investigations may lead to new therapeutic interventions for DMD.

Keywords
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Summary for Lay Audience
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that affects 1 in every
3000 boys. The most common symptom of DMD is muscle cell death and tissue
degeneration.

The body will naturally attempt to repair the damages by triggering an

inflammatory response to remove the cellular debris of cells that undergo apoptosis, also
known as programmed cell death. Muscle stem cells, cells that can become muscle cells, will
then be activated and undergo cell division to repair the damages. Additionally, nearby blood
vessels will undergo angiogenesis, the process of forming new blood vessels from
preexisting vessels, to supply the regenerating tissue with sufficient nutrients and oxygen that
is needed for tissue repair. Unfortunately, angiogenesis appears to be impaired in DMD,
leading to the formation of immature vessels that are incapable of functional perfusion (i.e.
supplying the necessary nutrients and oxygen needed for repair). To treat this vascular defect,
our lab has shown that the administration of angiopoietin-1 (Ang1) can stimulate the
formation of new functional vessels that are capable of functional perfusion. Ang1 is a
vascular stabilizing factor that binds to the Tie2 receptor on the surface of endothelial cells
and triggers a cascade of signaling effects that help maintain vasculature integrity and help
the maturation of angiogenic vessels. Although we have shown that Ang1 can help repair
vascular defects, Ang1 signaling has not been previously characterized in DMD. In this
study, we aimed to evaluate Ang1 signaling, including the expression of its antagonist
angiopoietin-2 (Ang2), receptor Tie2 expression and activation, and further downstream
targets protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) activation. From
our results, we show that Ang1 is expressed less in DMD mouse models compared to healthy
mice, while more Ang2 is being produced. This difference may shift the Ang1/Ang2
concentration ratio towards Ang2 and lead to the decrease in activated Tie2/total Tie2 ratio
seen in this study. These findings suggest that Ang1 signaling is reduced in DMD and
warrants further investigation that may need to development of new therapeutic options for
DMD patients.
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Introduction

1.1 Duchenne Muscular Dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is an X-linked recessive progressive neuromuscular
disease. It affects 1 in 3000-5000 boys, making it the most severe and common form of male
pediatric muscular dystrophy (Darras et al., 2014; Zellweger et al., 1975). DMD is typically
diagnosed between three to five years of age (Ciafaloni et al., 2009). DMD occurs due to
mutations in the dystrophin gene, leading to an absence of the dystrophin protein (Mercuri et
al., 2013). Cardiac and respiratory muscles are severely affected, often resulting in cardiac
failure or respiratory impairment that severely reduces life expectancy in patients (Bach et
al., 2011; Passamano et al., 2012).

1.2 Diagnosis of DMD
Initial diagnosis of DMD is done through the evaluation of creatine kinase (CK) levels
following the appearance of suggestive symptoms, including Gower’s sign and weakness in
the proximal lower limbs (Yiu et al., 2015). If CK levels are found to be elevated by 10-20
times the normal values, then genetic testing is conducted to evaluate for deletion or
duplication of the dystrophin gene using multiplex ligation-dependent probe amplification
(MLPA) or a comparative genomic hybridization array (del Gaudio et al., 2008; Stuppia et
al., 2012). If genetic testing is inconclusive, a muscle biopsy sample must be obtained and
evaluated for dystrophin expression by immunohistochemistry or western blot analysis
(Belfall et al., 1988; Hoffman et al., 1988).

1.3 Pathology of DMD
DMD results from spontaneous or inherited mutations in the DMD gene coding for
dystrophin (Abbs et al., 2010; Derek et al., 2002). DMD is the largest known gene in the
human genome, with a length of over 2200 kb and containing 79 exons. The majority of
mutations are deletions spanning from one to several exons resulting in a shift in the reading
frame, with point mutations and exonic duplications accounting for the remaining types
(Flanigan et al., 2009; Tuffery‐Giraud et al., 2009). The result is the formation of mutated
dystrophin transcripts that are subject to degradation by nonsense-mediated decay. In less
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severe cases where the mutation results in the production of partially functional dystrophin,
patients are diagnosed with Becker’s muscular dystrophy (BMD). Patients with BMD have
longer life spans and will experience milder symptoms compared to DMD patients (Bushby
et al., 1993).
Dystrophin is a 427 kDa cytoplasmic protein predominantly expressed in cardiac, smooth,
and skeletal muscles but its isoforms can also be found in endothelial cells, neurons of the
brain, and Schwann cells. Structurally, dystrophin functions to link the myofiber cytoskeleton
to the extracellular matrix via the dystrophin-associated protein complex (DPC) (Inna et al.,
2000). The DPC is composed of proteins that can be categorized based on their cellular
location within the DPC (Fig. 1). The cytoplasmic group consists of dystrophin, dystrobrevin,
syntrophin, and neuronal nitric oxide synthase (nNOS). Here, dystrophin functions to link the
intracellular actin network to the DPC while dystrobevin and syntrophin anchor nNOS to
dystrophin. The transmembrane group consists of β-dystroglycan, sarcoglycan, and
sarcospan. Here, the sarcoglycan subcomplex associates with β-dystroglycan which itself
associates with dystrophin to form a connection to the extracellular proteins of the DPC.
Lastly, the extracellular group of DPC consists solely of α-dystroglycan, which functions as a
receptor for extracellular matrix ligands such as laminin, linking the DPC to the basal lamina
(Campbell et al., 1992). Working in unison with several other proteins, the DPC provides a
costamere scaffold for myocytes, dispelling contractile forces throughout the sarcolemma to
the basal lamina during muscle contractions (Gao et al., 2015). Additionally, the DPC
mediates mechanical signals between the intracellular and extracellular spaces.
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Figure 1. Dystrophin-associated protein complex (DPC)
Dystrophin links the actin cytoskeleton to the DPC which is connected to the extracellular
matrix through laminin connections. This provides structural integrity to the muscle cell
sarcolemma during muscle contractions. Dystrophin also recruits other proteins such as
nNOS to the sarcolemma.
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The absence of dystrophin results in the inability of myofibers to cope with mechanical
stress. Hence during muscular contractions, the sarcolemma tears, resulting in an influx of
extracellular components into the intracellular space. The influx of Ca2+ into the cytosolic
space triggers the activation of cellular calpain proteases, ultimately resulting in plasma
membrane protein cleavage and apoptosis. Necrosis ensues, leading to the expression of proinflammatory cytokines and producing a sustained innate immune response (Deconinck et
al., 2007). Elevated levels of immunoglobulins IgA and IgG, as well as the release of CK and
lactate dehydrogenase (LDH) from degenerating myofibers, have thus been used as markers
of muscle damage. Tissue infiltration by inflammatory cells such as M1 (classically
activated) and M2 (alternatively activated) macrophages and lymphocytes lead to cytokine
secretion and subsequent effector cell activation and extracellular matrix production (Porter
et al., 2002). The excess deposition of matrix proteins leads to tissue rigidity and fibrosis,
which is compounded throughout the life of the patient, resulting in the replacement of
functional skeletal muscle with fibrotic and adipose tissue (Mann et al., 2011; Rockey et al.,
2015). As cycles of muscle degeneration and regeneration occur, the rate of regeneration
diminishes over time, eventually leading to severe muscle atrophy and fibrosis within the
dystrophic tissue.

1.4 Muscle Ischemia in DMD
Nitric oxide (NO) within the skeletal muscle mediates cell-cell interactions, muscle
contraction, glucose metabolism, and importantly, vasodilation. The production of NO in
skeletal muscles by neuronal nitric oxide synthase (nNOS) is mediated through signals
exchanged between the physical interaction of nNOS and dystrophin as part of the DPC
(Brenman et al., 1995; Shiao et al., 2004). In the absence of dystrophin and subsequent
disruption of the DPC, nNOS dissociates from the sarcolemma to the cytosol and is
downregulated (Brenman et al., 1995; Mikael et al., 2000). Functionally, through a process
known as functional sympatholysis, nNOS-derived NO acts as a local paracrine signal and
attenuates sympathetic vasoconstriction in response to increased metabolic loads (Tidball et
al., 2014). Thus, reduced sarcolemmal nNOS-derived NO impedes the skeletal muscle’s
ability to regulate vasodilation and results in reduced blood flow and local functional muscle
ischemia. Gail et al. found that the mdx mouse, a model of DMD, displayed an inability to
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attenuate α-adrenergic vasoconstriction that is phenotypically similar to nNOS-deficient mice
(Gail et al., 1998). Indeed, recovery of nNOS activity in a transgenic mdx mouse alleviates
the functional muscle ischemia present in normal mdx mice (Wehling et al., 2001).
Endothelial nitric oxide synthase (eNOS) is another NOS isoform that is constitutively
expressed in the vascular endothelium. It is activated by cytosolic increases in Ca+ and by
phosphorylation at Ser-1177 mediated by upstream kinases (Fleming, 2010). eNOS-derived
NO crucially regulates vascular tone and modulates the effects of numerous angiogenic
factors. During angiogenesis, vascular endothelial growth factor (VEGF)-mediated, and
eNOS-dependent NO production directly functions to increase vascular permeability and
induce endothelial cell migration and proliferation (Namba et al., 2003). Although eNOS
expression is found primarily in the arteries and decreases towards the microvessels, it assists
in regulating microvessel circulation and helps facilitate angiopoietin-1 (Ang1) mediated
capillary formation (Babaei et al., 2003). eNOS within endothelial cells forms a complex
with dystrophin and caveolin-1 (Cav-1) at the caveolae. In the absence of dystrophin, eNOS
is not localized to the caveolae, altering its activation (Feron et al., 2006; Ferruccio et al.,
2000). Indeed, a reduction in NO production in endothelial cells isolated from mdx mice has
been reported (Palladino et al., 2013). Attempts at increasing eNOS expression have resulted
in beneficial effects in DMD (Dabiré et al., 2011).

1.5 Pre-clinical Mouse Models of DMD
Among the numerous animal models of DMD, the mdx mouse model is the most used and
well-studied (McGreevy et al., 2015). The mdx mouse possesses a spontaneous nonsense
point mutation in exon 23 resulting in a lack of functional dystrophin. However, despite the
absence of functional dystrophin, mdx mice are spared of most clinical symptoms
experienced by human individuals with DMD. The skeletal muscles of mdx mice are subject
to several phases of degeneration and regeneration. In the first two weeks after birth, mdx
skeletal muscle function and histology are indistinguishable from those of a healthy mouse.
After the third week, the muscles will undergo necrosis and display histological features of
myopathy such as centrally nucleated myofibers and inflammatory infiltrates. After 6 weeks,
most of the degeneration in the skeletal muscles such as the hind limb muscles will plateau as
levels of regeneration outpaces the level of degeneration. Up to this point, fibrosis, the
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hallmark of DMD symptoms, is nearly absent from the skeletal muscles with the only
exception being the diaphragm muscle (Desguerre et al., 2012; Stedman et al., 1991).
However, even within the diaphragm tissue where levels of degeneration and fibrosis
continuously progress, it is not significant enough to be life-threatening. Thus, mdx mice
typically only have their lifespans reduced by up to 19% (Chamberlain et al., 2007). In DMD
patients, fibrotic development and degeneration of the diaphragm is a major cause of death
and patient lifespans are often reduced by as much as 75% (Passamano et al., 2012). This
makes the mdx mice a sub-optimal model for studying the skeletal muscle degeneration
associated with DMD.
Part of the difference in pathology between DMD patients and the mdx mouse model may be
due to compensatory mechanisms, one of which is the upregulation of homologous proteins
capable of compensating for the absence of dystrophin. Utrophin is a dystrophin homolog
that also functions to strengthen the sarcolemma by linking the extracellular matrix (ECM) to
the cytoskeleton. Normally, utrophin is predominantly expressed during embryonic
development and regenerating muscles and is replaced by dystrophin upon myofiber
maturation. In adults, its expression is limited to the vascular smooth muscles, nerves,
endothelium, and neuromuscular junctions (Blake et al., 1996). However, within the mdx
mouse, utrophin is upregulated in skeletal muscles independent of regeneration, and capable
of compensating for the loss of dystrophin (Grady et al., 1997). Double knockout mdx/utrn-/mice missing both dystrophin and utrophin exhibit severe muscle pathology like those of
DMD patients and have a significantly shorter life span. The mdx/utrn-/- mouse displays
muscular dystrophy at four weeks of age, develops profound fibrosis by eight weeks of age,
and dies prematurely at approximately 20 weeks of age (Rafael et al., 1998). However, due to
their severe disease pathology and reduced lifespan, they are difficult to breed and care for
and are therefore unsuitable for long-term studies. Thus, the intermediate mdx/utrn+/- model
is more manageable (Fig 2). Mdx/utrn+/- do not express dystrophin but have only one
functional utrophin allele which results in a disease phenotype that is similar to that of a
human DMD patient. Indeed, our lab has previously demonstrated that the mdx/utrn+/- mouse
displays significant tissue degeneration and fibrosis in the diaphragm that is absent in the
mdx mouse, but at a lower rate than the mdx/utrn-/- mouse (Gutpell et al., 2015). This makes
the mdx/utrn+/- mouse model an ideal model for studying DMD disease progression.
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Figure 2. Mouse models of DMD
Wild-type (WT), mdx, mdx/utrn+/-, and mdx/utrn-/- mice differ through their alterations in
dystrophin and utrophin expression. Disease severity is greatest in the mdx/utrn+/-, and
mdx/utrn-/- mice due to their absence of both dystrophin and utrophin. Disease severity also
increases in the mdx/utrn+/-, and mdx/utrn-/- mice due to their progression of fibrosis which is
absent in both WT and mdx mice.
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1.6 Muscle Regeneration in DMD
Physiological skeletal muscle regeneration is a product of efficient collaboration between
myogenesis and angiogenesis. Capillarization and the cross-sectional area of individual
regenerating myofibers both increase during skeletal tissue regeneration as angiogenesis and
myogenesis are seen to occur concomitantly (Latroche et al., 2017). Wound healing first
begins after the activation of quiescent satellite cells, which are myogenic stem cells situated
between the plasma membrane of the myofibers and the basal lamina (Fig. 3). After
activation, myogenic satellite cells may undergo symmetrical cell division (producing two
identical daughter stem cells) to replenish the stem cell pool, or asymmetrical cell division
(producing a daughter stem cell and a committed progenitor daughter cell). The committed
cell will subsequently differentiate into myoblasts and myocytes, capable of fusing with
existing myofibers or fusing to form new myofibers to repair the damaged muscle fibers (Yin
et al., 2013). Concurrently, transforming growth factor beta (TGFβ) expressed by
inflammatory cells will signal effector cells such as fibroblasts and myofibroblasts to
synthesize extracellular matrix proteins such as collagen I and collagen III, fibronectins,
proteoglycans, and fibrinogen while inhibiting the production of ECM proteases such as
collagenase and promoting protease inhibitors such as tissue inhibitors of metalloproteinases
(TIMPs) and plasminogen activator inhibitor type-1 (PAI-1) to construct a temporary ECM
(Delaney et al., 2017). This temporary ECM functions as a scaffold for regenerating
myofibers and is crucial in guiding the formation of neuromuscular junctions. Likewise, the
degradation of this ECM results in the formation of protein fragments that serve specific
functions during the tissue repair process. The orchestrated formation and degradation of this
temporary ECM is orchestrated by several cell types, proteases, and respective inhibitors
upregulated during the initial tissue regeneration. An imbalance of these specific proteins can
lead to aberrant ECM accumulation within the regenerating tissue, commonly known as
fibrosis (Mann et al., 2011).
Of equal importance is the formation of new blood vessels for oxygen and metabolite
delivery to sites of muscle regeneration. Development of new vascular networks are initiated
upon stimulation by several angiogenic factors such as VEGF, acidic fibroblast growth factor
(aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), hypoxia-
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inducible factor-1 (HIF-1α), and angiopoietin 2 (Ang-2), released by satellite cells,
inflammatory cells, and fibroblasts (Folkman et al., 1987). The angiogenic cascade then
proceeds, leading to endothelial cell activation, proliferation and migration, and invasive
capillary sprouting. The activated endothelial cells will differentiate into tip and stalk cells.
Tip cells function to sense angiogenic factors and will invade toward the angiogenic stimulus
while simultaneously expressing proteolytic enzymes to degrade the ECM to make way for
new vessels. Stalk cells follow closely behind the tip cells, proliferating into organized 3D
lumen structures as the new vessel elongates. As the tip cell approaches neighbouring
sprouts, it will fuse with the encountered sprout in a process known as anastomosis to
generate connecting vessel loops (Blanco et al., 2013). To complete the angiogenic process,
endothelial cells will express platelet-derived growth factor BB (PDGF-BB) that leads to the
recruitment of peri-endothelial support cells known as pericytes. Pericytes will then facilitate
vessel maturation via induction of endothelial cell quiescence and endothelial tight junctions’
stabilization (Stratman et al., 2010).
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Figure 3. Physiological muscle regeneration
Tissue damage first activates an inflammatory response that leads to the emigration of
inflammatory leukocytes into the damaged tissue for clearance of cellular debris. Muscle
regeneration follows through the activation of satellite cells and the initiation of the
angiogenic cascade. Remodeling and maturation of the regenerative phase are completed
after myoblasts repair the tissue damage through the formation of new myofibers and new
mature vessels.
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Pericytes are a heterogenous population of mesenchymal cells that reside in the basement
membrane of the microvasculature (Attwell et al., 2016). Primarily found to be associated
with capillaries, their presence is also associated with higher-order vessels such as arterioles,
venules, and veins, although they are notably absent from lymphatic vasculature. Distinctions
between pericytes and other peri-endothelial cells such as vascular smooth muscle cells
(vSMC) can be made through their anatomical location, round cell body morphology, and
numerous finger-like projections that extend along the length of the vessels ending in
physical contact with endothelial cells. Interestingly, lineage-tracing studies have shown that
pericytes in different tissues originate from diverse sources, ranging from hematopoietic,
endothelial, to macrophage origins, with evidence that pericytes from a single vessel having
different developmental origins (Yamazaki et al., 2018; Yamazaki et al., 2017). Nonetheless,
all pericytes, regardless of origin, play functional roles in the homeostasis of skeletal and
cardiac muscles by regulating blood vessel permeability and angiogenesis. After activation of
pericyte PDGFβ surface receptors via PDGF-BB released from endothelial cells, pericytes
will stabilize the vessel walls through paracrine signalling via Ang1 secretion (Bergers et al.,
2005; Fuxe et al., 2011). Ang1 will bind to Tie2 receptors on endothelial cells, inducing
vessel quiescence and maturation (Brindle et al., 2006; Fukuhara et al., 2010; Young Koh et
al., 2009). Pericyte density ranges between different tissue types. The brain has the highest
pericyte to endothelial cell ratio between 1:1 and 1:3 (Armulik et al., 2010), while a ratio of
1:100 is found in the skeletal muscle vasculature (Armulik et al., 2011; Shepro et al., 1993).
The difference in coverage appears to correlate with endothelial permeability properties,
endothelial cell turnover, and orthostatic blood pressure. However, evidence has suggested
that skeletal muscle pericyte density increases significantly in response to exercise-induced
angiogenesis (Baum et al., 2015).
Besides regulating vessel stability, skeletal muscle pericytes have been also implicated as a
potent tissue-resident progenitor with myogenic, fibrotic, and adipogenic potential (Fig. 4). A
subpopulation of pericytes expressing alkaline phosphatase (AP) and neural-glia antigen 2
(NG2) was found to be capable of entering the satellite compartment and differentiating into
myotubes following skeletal tissue injury (Dellavalle et al., 2011). Additionally, utilizing a
Nestin-GFP/NG2-DsRed double transgenic mice, Birbrair et al. demonstrated that only type
2 (Nestin+/NG2+) pericytes were capable of myogenic potential and fusing with myotubes,
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whereas type 1 (Nestin-/NG2+) pericytes were found to contribute to fibrosis and fat
accumulation (Birbrair et al., 2013). Recent evidence has implicated another EPH Receptor
A7 (EPHA7) positive subpopulation of pericyte capable of differentiating into both muscle
fibers and micro vessels upon transplantation into a DMD mouse model (Yoshida et al.,
2020). Further studies have shown that Noggin, expressed by newly formed muscle fibers, is
capable of recruiting NG2+ progenitors and promote their commitment to a myogenic fate
(Ugarte et al., 2012). Conversely, exposure of myoblasts to Notch Delta ligand 4 (Dll4) and
PDGF-BB downregulates myogenic genes, while promoting pericyte marker upregulation
and migration of these myoblasts to a perivascular position (Cappellari et al., 2013). While
this conversion was initially thought to only occur during embryonic development, recent
work by Gerli et al. has shown this mechanism to be conserved in adult murine and human
satellite cell-derived myoblasts (Gerli et al., 2019).
The relationship between satellite cells and pericytes, two central cells in myogenesis and
angiogenesis, respectively, is thus crucial in maintaining muscle homeostasis and regulating
muscle regeneration. As previously mentioned, satellite cells are located beneath the
basement membrane of the myofibers, situating them directly adjacent to capillaries and in
close proximity to pericytes. Skeletal muscle pericytes have been shown to directly promote
the satellite cell niche, regulating satellite cell quiescence and myogenesis through Ang1 and
insulin-like growth factor 1 (IGF-1) signalling, respectively (Kostallari et al., 2015). Pericyte
ablation has been shown to result in myofiber hypotrophy and impaired satellite cell
quiescence (Kostallari et al., 2015). Thus, both myogenesis and angiogenesis in DMD may
be severely impaired.
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Figure 4. Pericyte functions in skeletal muscles
Pericytes are a population of mesenchymal cells capable of differentiating into several
different cell types and capable of performing a multitude of functions to maintain
homeostasis (blue), respond to injury (green), and amplification of pathological responses
(red).
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1.7 Myogenesis in DMD
Regenerative myogenesis following an acute injury stabilizes after the establishment of new
myofibers and the conclusion of the inflammatory response. However, in DMD, as
previously mentioned, the newly developed myofibers are susceptible to further damage,
resulting in continuous cycles of muscle degeneration, chronic inflammation, regeneration,
and ultimately, the depletion of the satellite cell pool over time (Fig. 5). Additionally, the
absence of dystrophin within satellite cells results in a loss of cell polarity, aberrant
asymmetric cell division, and altered myogenic commitment, resulting in reduced myogenic
progenitor generation during tissue regeneration (Chang et al., 2016; Dumont et al., 2015).
Myogenic pericytes populations, shown to contribute as much as 7% of the regenerated
myofibers in diaphragm muscle tissues, had reduced myogenic capabilities within aged
dystrophic mice and patients (Dellavalle et al., 2007). The decrease in pericyte and satellite
cell populations is heavily associated with age, as both cell types are highly expressed within
young patients but dwindle significantly in older individuals. Compounding on pathogenic
myogenesis is the onset of fibrosis. The aberrant accumulation of ECM leads to a loss of
tissue architecture and motile and contractile function of the skeletal muscle, while
simultaneously reducing the regenerative capabilities of the tissue due to suboptimal fibrotic
microenvironments characterized by profound chronic inflammation. Consequently, while
fibro/adipocyte progenitor (FAPs) are a major source of myofibroblasts, ADAM
metallopeptidase domain 12 (ADAM12) and platelet derived growth factor receptor alpha
(PDGFRα) positive cells have been linked to muscle fibrosis (Dulauroy et al., 2012;
Ieronimakis et al., 2016). Indeed, PDGFRα+ pericytes have been shown to be fibrogenic in
vitro when cultured with TGFβ (Chen et al., 2011). Lastly, through lineage tracing,
ADAM12+ and PDGFRβ+ myofibroblast progenitors with pericyte characteristics were found
to be responsible for a significant majority of differentiated myofibroblasts following
cardiotoxin-induced muscle injury (Dulauroy et al., 2012). It is evident that myogenesis in
DMD is dysregulated, severely hindering the endogenous regenerative capabilities of the
tissue.
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Figure 5. Pathological regeneration
Following an acute injury, an acute inflammatory response is triggered that precedes normal
muscle regeneration. In DMD, chronic tissue degeneration triggers chronic inflammation in
which physiological regeneration is unable to surpass the rate of degeneration resulting in
pathological regeneration where inflammation and fibrosis are profound.
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1.8 Angiogenesis in DMD
Dystrophin, although originally thought to be a myocyte-specific protein, is also expressed in
endothelial cells (Loufrani et al., 2001). Several vascular abnormalities have been thus noted
to affect DMD pathology. The absence of dystrophin impairs the endothelium’s ability to
perform flow-induced dilation. Evidence of grouped necrotic fibers within muscles of DMD
patients was partially explained through the presence of ischemia denoted by lack of
capillaries in the affected area. A decreased in vasculature density within the tibialis anterior
(TA) and gracilis muscles of aged mdx mice compared to their wild-type counterparts has
been observed (Palladino et al., 2013). Morphologically, capillary and endothelial cell areas
were demonstrated to be much greater in muscle biopsies of DMD patients relative to control
subjects (Miike et al., 1987). Like myogenesis, few angiogenic abnormalities are associated
with early disease progression. For example, Straino et al. presented evidence for a normal
angiogenic response within hindlimb muscles of mdx mice while Palladino et al. reported
impaired angiogenic responses within mdx mice with a reduction in endothelial cell
migration, proliferation, and tube formation (Palladino et al., 2013; Straino et al., 2004).
Though initially thought to be contradicting evidence, the difference could be explained by
the age of the animal models used within each respective study. Palladino et al. used mature
6-month-old mdx mice, while Straino et al. used young 2-month-old mdx mice that may still
retain their potent regenerative capabilities. Utilizing a Flk-1GFP/+ mdx mouse model,
Latroche et al. demonstrate a significant decrease in muscle perfusion in 12-month-old
dystrophic mice compared to their 3-month-old counterparts (Latroche et al., 2015).
Sprouting angiogenesis occurs in specific coordinated steps. Firstly, in response to a hypoxia
environment, parenchymal cells will begin secreting the pro-angiogenic factor VEGF,
forming an extracellular cytokine gradient that will act to guide migrating angiogenic cells
(Gerhardt et al., 2003). The resulting VEGF signaling cascade leads to the degradation of the
local basement membrane and the detachment of pericytes. Endothelial cells exposed to the
highest levels of VEGF will then differentiate into endothelial tip cells, while its
neighbouring endothelial cells differentiate into endothelial stalk cells. The tip cells form
lamellipodia and filopodia that function to navigate and migrate the developing sprout
towards the angiogenic stimulus gradient (De Smet et al., 2009). Following closely behind
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the tip cells, stalk cells will begin to proliferate, elongate, and organize into pre-mature
luminal structures. Upon contact with other capillaries or sprouts, the developing sprout will
undergo anastomosis. Vascular remodeling that modulates vessel diameter and directional
flow is then mediated by the expression of Ang1. Lastly, vascular maturation is achieved
through Ang1-mediated pericyte recruitment and stabilization of the endothelial adheren
junctions.
Both VEGF and HIF-1α are two prominent angiogenic factors expressed by satellite cells
during muscle regeneration. Satellite cells isolated from aged, 12-month-old mdx mice
demonstrated reduced expression of both VEGF and HIF-1α, leading to reduced angiogenic
capabilities in vitro (Rhoads et al., 2013). Importantly, our lab has shown a significant
reduction in VEGF and Ang1 concentration in fibrotic diaphragm tissue of mdx/utrn+/- mice,
possibly resulting in deficiencies in both angiogenesis initiation and angiogenesis maturation
(Gutpell et al., 2017). Thus, it is possible that with the absence of dystrophin in endothelial
cells resulting in an impaired angiogenic response in combination with a lack of angiogenic
factors, the vascular network in DMD is severely compromised and unable to support
endogenous muscle repair.
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Figure 6. Sprouting Angiogenesis
Sprouting angiogenesis occurs in distinct steps. 1) Angiogenesis will begin upon the
secretion of pro-angiogenic signals such as VEGF. 2) Endothelial cells will respond to the
pro-angiogenic signals, resulting in detachment of pericytes and breakdown of the basement
membrane. 3) Endothelial cells closest to the angiogenic signal will differentiate into tip cells
that will migrate towards the signal. Neighbouring endothelial cells will differentiate into
stalk cells that proliferate behind the tip cells. 4) The proliferating stalk cells will organize
into pre-mature tubes. 5) The newly formed vessel will undergo remodeling upon signaling
by Ang1. 6) Vessel maturation occurs through Ang1-mediated pericyte recruitment and
stabilization of the adhesion junctions.
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1.9 Current Therapies
Current treatments available for DMD only target the specific symptoms that DMD patients
endure. Corticosteroid treatments are often started around the age of five, functioning to slow
the rate of tissue degeneration and increase muscle strength (Darras et al., 2014; Passamano
et al., 2012). Other complications such as respiratory infections and cardiac dysfunctions are
treated with the use of antibiotics and angiotensin-converting enzyme inhibitors, respectively
(Bach et al., 2011). While there are currently no commercially available cures, the restoration
of dystrophin expression and subsequent DPC repair is seen as the definitive curative
treatment for DMD. Recent advancements in gene therapy variants, exon skipping, and stem
cell therapy to restore dystrophin production have been promising.
The use of recombinant adeno-associated viral vectors in the delivery of dystrophin gene
fragments has resulted in the expression of functional dystrophin in animal models as well as
in human patients. However, due to the large size of the dystrophin gene, these viral vectors
are unable to carry the entire dystrophin gene. Instead, they carry a modified microdystrophin gene that lacks some dystrophin gene functions and results in reduced
transduction efficiency (Duan, 2018; Kupatt et al., 2021). Two examples are the
investigational gene therapy PF-06939926 developed by Pfizer (ClinicalTrials.gov Identifier:
NCT04281485) and SRP-9001 developed by Sarepta (ClinicalTrials.gov Identifier:
NCT03769116). PF-06939926 is currently undergoing Phase 1b trials in the United States
and has recently entered Phase 3 trials at sites in Italy, Israel, and Spain with plans to expand
to other countries, while SRP-9001 is expected to enter Phase 3 trials in the near future. Exon
splicing has also been employed as a method of inducing functional dystrophin expression
for individuals with mutations at specific vulnerable exons (Kupatt et al., 2021). Sarepta’s
Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is the first exon-skipping
drug approved by the US Food and Drug Administration (FDA) for the treatment of DMD
for patients with specific exon 51 mutations. Another gene-editing strategy known as
clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) has shown to
be effective in inducing dystrophin expression and improving muscle contractility in animal
models of DMD. CRISPR-mediated exon skipping combines the two methods to utilize the
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Cas9 protein and guide RNAs to target splicing regulatory sites, creating INDEL mutations
and single-base changes that induce exon skipping (Zhang et al., 2020).
Stem cell therapy, in which mesenchymal or embryonic stem cells (ESC), derived either
from donors or reprogrammed cells from the patient themselves, are implanted into patients
to generate healthy dystrophin-expressing muscle fibers that fuse with the patient’s
dystrophic muscle fibers, has been met with complications. Goudenege et al. demonstrated
that when MyoD expressing human ESC grown in myogenic culture mediums were
transplanted into immunodeficient mdx mouse, they indeed participated in muscle
regeneration and formed dystrophin expressing myofibers. However, their efficacy dropped
significantly when transplanted into inflamed muscle fibers (Goudenege et al., 2012).
A significant obstacle that stem cell therapy and other regenerative treatments face is the
inflamed and fibrotic microenvironment in which these therapies are introduced into. This
microenvironment is not favourable for tissue regeneration, and thus, any myogenic approach
designed to re-introduce dystrophin is unable to fulfill its purpose. In the case of stem cells,
inflammation and fibrosis devastate a patient’s stem cell niche, the microenvironment
necessary for the stem cell’s proliferation and differentiation (Lane et al., 2014). This reduces
the engraftment, survival, proliferation, and function of the transplanted cells. Additionally, a
decrease in oxygen and nutrient delivery to the tissues caused by the previously mentioned
vascular defects cripples the tissue’s endogenous repair process (Mikael et al., 2000). With
reduced blood perfusion, the delivery of viral vectors and stem cells alike is severely
hindered. Immunosuppressive agents such as tumor necrosis factor (TNF) inhibitors and
nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB) inhibitors
administered in combination with the gene therapy are being tested (Miyatake et al., 2016).
However, without addressing both muscle ischemia and the hostile microenvironment
simultaneously, it is unlikely that these dystrophin restorative therapies will be completely
effective. Thus, the addition of a vascular therapy to treat muscle ischemia and enhance
endogenous muscle regeneration has been proposed (Ennen et al., 2013; Palladino et al.,
2013; Podkalicka et al., 2019; Shimizu-Motohashi et al., 2014). Evidence has shown that
increasing vasodilation and blood flow via phosphodiesterase-5 (PDE-5) inhibitors reduce
myofiber damage in mdx mice and rescues functional muscle ischemia in patients (Batra et
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al., 2019; Nelson et al., 2014). Lastly, induced VEGF overexpression results in significant
increases in endogenous muscle regeneration evident by an increase in the number of
myogenin-positive satellite cells and the number of regenerating myofibers (Messina et al.,
2007). However, while VEGF treatment appears promising, the sole usage of VEGF in
correcting the vascular defects of DMD has been challenged. One area of concern is the
dosage of VEGF given to a patient considering evidence that long-term exposure to high
VEGF dosages can lead to the formation of hemangiomas and vascular tumours (Carmeliet,
2000; Lee et al., 2000; Springer et al., 1998). Furthermore, our lab has shown that
intramuscular administration of VEGF into the gastrocnemius muscle of mdx/utrn+/- mouse
does not improve blood perfusion nor does it decrease collagen deposition (Gutpell et al.,
2017). Interestingly, our lab has shown that administration of VEGF in combination with
Ang1 improves blood flow and reduces fibrosis. Subsequent sole administration of Ang1 into
gastrocnemius muscles of mdx/utrn+/- mice increased vascular density, vessel maturation, and
decreased collagen deposition (Gutpell et al., 2017). Thus, is it vital to characterize the
endogenous expression and activation of the Ang/Tie2 signalling pathway due to its role in
vascular homeostasis and angiogenesis.

1.10 Angiopoietin-Tie Signalling Pathway
1.10.1

Overview

The angiopoietin-Tie (Ang/Tie) signalling pathway is a crucial pathway involved in
modulating angiogenesis, blood and lymphatic vessel development, and vascular quiescence,
permeability, and stability (Brindle et al., 2006; Fukuhara et al., 2010; Young Koh et al.,
2009). Dysregulation of the Ang/Tie signalling pathway can lead to poor outcomes. In the
cardiovascular system, vascular impairment, ischemia/reperfusion injury, development of
atherosclerotic plaques, and peripheral arterial disease have all been linked to dysfunctional
Ang/Tie signalling (Fujisawa et al., 2017; Yeboah et al., 2017). In diabetic macular edema,
abnormal Ang/Tie signalling leads to vascular leakage and disrupted retinal and choroidal
neovascularization (Whitehead et al., 2019). Ang/Tie2 signalling has also been heavily
implicated in tumour angiogenesis and inflammation (U. Fiedler et al., 2006; Kobayashi et
al., 2005; Metheny-Barlow et al., 2003).
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The acronym Tie stands for tyrosine kinase with immunoglobulin and EGF homology
domains. Originally identified as the second endothelial cell-specific receptor tyrosine kinase
signalling system following the VEGF-VEGFR system, the Tie receptors, Tie1 and Tie2, are
expressed on both blood and lymphatic endothelial cells (Fukuhara et al., 2010; Wong et al.,
1997). Tie2 appears to be constitutively expressed on endothelial cells. Tie1 expression
appears to be more heavily regulated and is found to be downregulated in the adult quiescent
vasculature but upregulated in response to hypoxia, embryonic and adult angiogenesis, and
malignant melanoma progression (McCarthy et al., 1998). Both have been found to be
expressed on circulating hematopoietic cells including megakaryocytes, monocyte, satellite
cells, hematopoietic stem cells in the bone marrow, and pericytes. Structurally, Tie1 and Tie2
share a 76% identity in their intracellular tyrosine kinase domains (Schnurch et al., 1993).
Their extracellular domains are only 33% identical, leading to their different ligand
associations. Tie1 binds to leukocyte cell-derived chemotaxin 2 (LECT2), primarily
functioning to modulate Tie2 activation (Xu et al., 2019). Previous evidence has shown that
Tie1/Tie2 heterodimer formation is necessary for Tie2 phosphorylation and downstream
target activation. However, contradicting studies have shown that Tie1/Tie2 heterodimer
disassociation and Tie2/Tie2 homodimer formation upon Ang1 ligand binding leads to Tie2
phosphorylation and vascular stability (Seegar et al., 2010). Recent computational modeling
studies have shown that Tie2 activation is indeed sensitive to Tie1 expression, with higher
Tie2 activation associated with lower Tie1 expression (Zhang et al., 2019). Interestingly,
Tie1 functions to sustain Tie2 activation in remodeling stalk cells while negatively regulating
Tie2 expression on tip cells during angiogenesis (Savant et al., 2015). Tie2 activation by
either Ang1 or angiopoietin-2 (Ang2) leads to the release of ligands and Tie2 receptor
phosphorylation, internalization, and subsequent degradation (Bogdanovic et al., 2006). Due
to endocytosis of the Tie2 ligand which results in an overall decrease in available surface
receptors, it has been hypothesized that Tie1’s context-dependent modulation of Tie2
activation is enabled through its formation of Tie1/Tie2 heterodimers that prevents rapid Tie2
internalization and allows for sufficient Tie2 to perpetuate its downstream signalling. Thus,
Tie1 indirectly mediates Ang1/Tie2’s vascular stability and EC anti-apoptotic phenotype.
The angiopoietin family of proteins consists of Ang1, Ang2, angiopoietin-3 (Ang3), and
angiopoietin-4 (Ang4) (Fagiani et al., 2013). Ang1 and Ang2 are the main ligands for Tie2
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while Ang3 and Ang4 are respective mice and human orthologues. Ang1 is the primary Tie2
agonist. Ang1-Tie2 binding leads to the disassociation of the Tie1/Tie2 heterodimer and
formation of Tie2 homodimers and downstream signal transduction (Seegar et al., 2010).
Natively found in dimers, trimers, tetramers, and higher order multimers, only tetrameric or
higher multimeric forms of Ang1 appear capable of activating Tie2 (Kyung-Tae et al., 2005).
Ang1 is found to be constitutively expressed by pericytes, vSMCs, fibroblasts, osteoblasts,
and tumour cells (Fagiani et al., 2013). Ang1 upregulation is associated with angiogenesis,
while its downregulation is associated with TNF-α and IL-1B expression. After expression,
Ang1 associates with the ECM through its linker peptide region. Ang1 deletion results in
premature embryonic lethality with severe heart defects and an immature vasculature
network lacking proper pericyte attachment and complexity (Jeansson et al., 2011).
Conversely, transgenic expression of Ang1 leads to capillary diameter enlargement,
increased endothelial cell proliferation, and increased pericyte coverage (Cho et al., 2005).
Ang2 primarily functions as the competitive antagonist to Ang1 and acts to inhibit Tie2
signalling. However, in experimental settings, Ang2 has been shown to be a weak Tie2
agonist in conditions where Tie1 is present and Ang1 is absent (Yuan et al., 2009). Unlike
Ang1, Ang2 exists solely as lower-order multimers, such as dimers, trimers, and tetramers.
Ang2 is primarily expressed by endothelial cells and is transcriptionally induced in response
to hypoxia, high glucose concentration, shear stress, TNFα, and VEGF. Within quiescent
endothelial cells, Ang2 is transcriptionally repressed by the transcription factor Kruppel-like
factor 2 (KLF2) (Nayak et al., 2011). Endogenous and overexpressed Ang2 are stored within
specialized endothelial storage granules called Weibel-Palade bodies (WPB). Stored Ang2
has a half-life of over 18 hours and can be rapidly released in seconds to minutes upon
stimulation via WPB secretagogues such as phorbol 12-myristate-13-acetate (PMA),
thrombin, and histamine (Fiedler et al., 2004). However, while Ang2 concentrations within
WPB are detectable in quiescent vasculature, expression appears to vary dramatically
depending on the tissue of origin. Prominent Ang2 expression and storage were found in the
brain and within the female reproductive system while hardly detectable in skeletal and
cardiac muscles (Akwii et al., 2019; Mofarrahi et al., 2011). Ang2-null mice develop chylous
ascites shortly after birth and demonstrate an inability to fully initiate an inflammatory
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response. Transgenic overexpression of Ang2 results in embryonic lethality mirroring Ang1null and Tie2-null mice (Peter et al., 1997).
Ang3 and Ang4 are respectively mouse and human orthologues. Contextually, recombinant
Ang3 has been shown to induce Tie2 phosphorylation in murine endothelial cells. However,
when overexpressed, Ang3 may act as a Tie2 antagonist through inhibition of Ang1-Tie2
activation (Lee et al., 2004). Ang3 does not appear to induce Tie2 phosphorylation in human
cells, however, Ang4 has been shown to be a potent Tie2 agonist in vitro with human
umbilical vein endothelial cells (HUVECs). Both Ang3 and Ang4 induced angiogenesis in
vivo in mouse corneal micropocket assays (Lee et al., 2004). Conversely, Ang3 and Ang4
have differing tissue expression distributions in their respective species. Significant Ang3
expression can be found in the heart, kidney, and testis tissue of mice while Ang4 expression
is primarily isolated to human lung tissue. Both Ang3 and Ang4 expression are shown to be
induced in response to hypoxia. However, no specific molecular mechanisms of expression
for neither proteins have been well described. Neither protein is significantly expressed in
skeletal muscle tissues.
Ang/Tie2 signalling can be modulated by several different endothelial and myocyte integrins
to differing effects (Avraamides et al., 2008). Integrin α5β1 interacts with Tie2 in a
fibronectin-dependent manner to facilitate increases in Ang1 mediated phosphorylation of
Tie2, p85 subunit of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signalling, and
support Tie2 localization and complex formation at the endothelial cell-endothelial cell
junction (Ilaria et al., 2005; Pang et al., 2018). Conversely, α5β1 can also directly interact
with Ang2 released by tip cells to mediate endothelial monolayer destabilization during
angiogenesis (Felcht et al., 2012). In skeletal and cardiac myocytes, integrin-Ang1
interactions elicit activation of pro-survival pathways including the PI3K/Akt pathway and
inhibited caspase-3 activation. Consequently, the opposing effects of Ang1 and Ang2
signalling also extend to integrin interactions. In diabetic retinopathy, retinal astrocyte αvβ5Ang1 interactions facilitated the initiation of angiogenesis, inhibition of vascular leakage,
and reduced neuronal dysfunction (Lee et al., 2013). In contrast, astrocyte αvβ1-Ang2
interactions induced astrocyte apoptosis (Yun et al., 2016). Similarly, α3β1-Ang2
interactions in diabetic retinopathy have been linked to pericyte apoptosis (Park et al., 2014).
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Thus, Ang1 and Ang2 interaction whether it be with integrins or Tie2 helps facilitate the
angiogenic response as well as maintain vascular homeostasis.

1.10.2

Ang/Tie Signalling in Endothelium Homeostasis

Tie2 will undergo specific subcellular localization upon angiopoietin activation. This
localization helps differentiate the signalling outcomes between the quiescent and angiogenic
endothelium (Kodama et al., 2008; Wong et al., 1997). In motile angiogenic endothelium,
matrix-bound Ang1 binds to Tie2 and localizes it to cell-extracellular matrix contacts, and
proceeds with cell migration and proliferation processes. In quiescent endothelium,
Ang1/Tie2 signalling translocate Tie2 on confluent endothelial cells into clusters at the
endothelial cell-endothelial cell junctions and induces pro-survival, endothelial tight junction
stabilization, and anti-inflammatory signals. This is primarily achieved through downstream
recruitment and activation of PI3K and subsequent Akt phosphorylation.
Akt signalling promotes endothelial cell survival though upregulation of pro-survival
molecules including phosphorylated eNOS and survivin expression, while simultaneously
suppressing apoptotic pathways such as caspase-9 and BAD (Shiojima et al., 2002; Somanath
et al., 2006). Ang1-mediated Akt signalling additionally leads to phosphorylation and
inhibition of the forkhead transcription factor FKHR (FOXO1) (Daly et al., 2004). FOXO1
activation has been heavily implicated in inducing endothelial cell apoptosis. Additionally,
FOXO1 is a prominent Ang2 transcription factor, thus, Tie2 phosphorylation directly inhibits
Ang2 expression and maintains Ang1/Tie2 signalling through a negative-feedback loop.
Another important transcription factor is KLF2. It is a shear stress-regulated transcription
factor that upregulates Tie2 expression while down-regulating Ang2 expression, thus
promoting a resting endothelium phenotype (Nayak et al., 2011).
Ang1/Tie2 signalling also promotes endothelial cell tight junction stability and limits vessel
permeability. Ang1 mediated activation of RhoGTPase Rac1 triggers the formation of
lamellipodia protrusions that colocalize with vascular endothelial cadherin (VE-cadherin;
also known as cadherin 5 (cdh5)) and stabilizes the endothelial cell-cell contact by promoting
the reorganization of the actin cytoskeleton into a cortical arrangement (David et al., 2011).
However, Rac1 is also capable of promoting the disassociation of the cell-cell contact
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depending upon which guanine nucleotide exchange factor (GEF) forms the complex with
Rac1. Similarly, the RhoGTPase RhoA, which normally signals the reorganization of the
actin cytoskeleton into a stress-fiber arrangement that promotes endothelial contractions,
exerts a different effect upon Ang1/Tie2 signalling. Ang1 mediated RhoA-GEF Syx complex
formation activates mammalian diaphanous (mDia) leading to its sequestration of the nonreceptor tyrosine kinase Src (Gavard et al., 2008; Ngok et al., 2012). This prevents Src
mediated VE-cadherin phosphorylation-dependent redistribution and internalization, thus
maintaining inter-endothelial cell stability. Indeed, in vitro administration of recombinant
Ang1 was able to inhibit vascular leakage induced by inflammatory cytokines and growth
factors such as VEGF, thrombin, and histamine (Gavard et al., 2008). VE-cadherin stability
also directly regulates Hippo-YES-associated protein (YAP) phosphorylation and subsequent
inhibition, another prominent Ang2 transcription factor critical to regulating vessel
remodeling (Choi et al., 2015). Pharmacological inhibition of vascular endothelial protein
tyrosine phosphatase (VEPTP), a prominent phosphatase inhibitor of Tie2, improved
endothelial barrier function, even in mice lacking cdh5 expression, through stabilization of
the cortical actin cytoskeleton via RAP1 activation and decreased myosin light chain 2
phosphorylation (Frye et al., 2015). Lastly, Tie2 phosphorylation also leads to the
recruitment of TNFAIP3 interacting protein 2 (ABIN2), which interferes with the NF-κB
pathway and inhibits the expression of leukocyte adhesion molecules VAM1 and ICAM1 to
promote an anti-inflammatory effect (Hughes et al., 2003; Tadros et al., 2003). Therefore,
Ang1 bestows a protective effect on the endothelium, promoting vascular homeostasis and
quiescence.
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Figure 7. Ang/Tie2 signalling in quiescent endothelium
Angiopoietin 1 (Ang1) mediated localization of Tie2 at inter-endothelial cell junctions leads
to Tie2 phosphorylation and activation of the p85 subunit of the phosphoinositide 3-kinase
(PI3K) which in turn phosphorylates protein kinase B (Akt). Phosphorylated Akt contributes
to enhancing cell-cell stability through activation of the RhoGTPase Rac1 via RAP1,
resulting in reorganization of the actin cytoskeleton into a cortical arrangement. RhoGTPase
RhoA also enhances inter-endothelial cell connections through activation of mammalian
diaphanous (mDIA) which sequesters the non-receptor tyr kinase Src and preventing Srcmediated VE-cadherin phosphorylation and subsequent internalization and degradation. Akt
signalling also confers endothelial cell pro-survival and anti-apoptotic effects through
expression of suvivin and endothelial nitric oxide synthase (eNOS) phosphorylation. The
anti-inflammatory effects of Ang1/Tie2 signalling are mediated through Akt directed
inhibition of the FOXO1 transcription factor and A20-binding inhibitor of NF-κB (ABIN2)
directed inhibition of NF-kB that inhibits expression of Angiopoietin 2 (Ang2), vascular cell
adhesion protein 1 (VCAM1), and intercellular adhesion molecular 1 (ICAM1), respectively.
Krupple-like factor 2 (KLF2) transcription factor upregulates Ang1 expression, ensuring
endothelial cell quiescence. Adapted from Young Koh et al., 2009.
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1.10.3

Ang/Tie2 in activated Endothelium and inflammation

Destabilization of the Ang1/Tie2 interaction and endothelium is necessary during various
physiological and pathological conditions including angiogenesis, vascular remodeling, and
when mounting an inflammatory response. In homeostatic endothelium, the Ang1/Ang2 ratio
is heavily favored towards Ang1 due to it being constitutively expressed, while Ang2 is
downregulated, allowing Ang1/Tie2 signalling to mediate vascular quiescence. However,
upon endothelial activation, the secreted Ang2 shifts the Ang1/Ang2 ratio towards Ang2
(Wang et al., 2017). In the current model, endothelial cells will respond to stimuli within
their microenvironment, secrete Ang2 from the WPB, which will sensitive the endothelial
cells to inflammatory stimuli and initiate an inflammatory response (Fiedler et al., 2006;
Scholz et al., 2011). Ang2 can act as a weak Tie2 agonist and has even been shown to enact a
protective effect upon endothelial cells (Daly et al., 2006). However, Ang2 only appears to
be a Tie2 agonist in the presence of Tie1 (Kim et al., 2016; Korhonen et al., 2016). In
activated endothelium and during inflammation, surface Tie1 is cleaved, shifting Ang2
activity into a strictly Tie2 inhibitory role and inhibiting Ang1/Tie2 signalling (Mueller et al.,
2016). The reduced Ang1/Tie2 signalling reduces RhoA activity, PI3K and Akt
phosphorylation, and increases vessel permeability through Src mediated VE-cadherin
phosphorylation and endocytosis and the detachment of pericytes from the basement
membrane. The reduction in Akt signalling and internalization of VE-cadherin further
perpetuates Ang2 signalling through FOXO1 and YAP mediated Ang2 transcription. Ang2
can also directly interact with β1-integrin to facilitate Tie2 independent destabilization of the
endothelium through formations of actin stress fibers (Hakanpaa et al., 2015). Elevated Ang2
concentrations have also been shown to induce endothelial cell detachment from the
endothelial monolayer and incite endothelial cell apoptosis (Scharpfenecker et al., 2005).
These cumulative changes perpetuated through Ang2 primes the endothelium to respond to
cytokine-mediated angiogenic and inflammatory signalling and allow for the infiltration of
angiogenic myeloid cells, leukocytes, inflammatory cytokines, respectively.
In angiogenesis, the Ang/Tie2 system contributes to its initiation, migration, and proliferation
of endothelial cells, the differentiation between tip and stalk cells, and maturation of the
newly formed vessels. Ang2 does not directly promote angiogenesis other than in a specific
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subpopulation of Tie2-negative endothelial cells, however, as previously mentioned, it
prepares the endothelium for the subsequent angiogenic cascade in response to angiogenic
factors such as VEGF and environmental cues like hypoxia. VEGF-stimulated sprouting
angiogenesis is directly associated with lower Tie2 surface presentations, thus inhibiting
vascular stabilization and promoting angiogenesis and vascular remodeling (Findley et al.,
2007). Importantly, Ang2 upregulation in the absence of an external stimulus such as VEGF
results in endothelial apoptosis and vessel regression (Holash et al., 1999; Ivan et al., 2002).
This can be seen in the regressing ovarian corpus luteum during luteolysis (Fraser et al.,
2003). Interestingly, evidence has shown that Ang2 appears to regulate VEGF expression at
the transcriptional level through inhibition of HIF-1α expression and HIF-DNA-binding
activity in Tie2 expressing cells, displaying a level of intrinsic coordination during
angiogenesis (Lee et al., 2008). Following initiation, endothelial cells will begin to proliferate
and migrate. Although Ang1 mediates endothelium quiescence and stability, it also
contributes to endothelial cell migration. Activation of the PI3K pathway in non-resting
endothelial cells leads to integrin-mediated signal transduction of focal adhesion kinase
(FAK) and cell migration (Zhao et al., 2011). Additionally, Dok-related docking protein
(Dok-R) can associate with Tie2 following Ang1 activation, recruit the Nck2 adapter protein,
and control Ang1-mediated endothelial cell migration (Jones et al., 2003). Sprouting
angiogenesis then proceeds through the differentiation of tip and stalk cells. Tip cells are
characterized by low Tie2 expression and high Ang2 expression, while stalk cells are
characterized through Tie2 expression (Savant et al., 2015). Transgenic inactivation of Ang2
reduces both the number of tip cells as well as resulting in fewer filopodia per tip cell. The
low Tie2 expression on tip cells is not only transcriptionally mediated, but on the surface,
upregulated Tie1 inhibits Tie2 surface presentation. However, in stalk cells, Tie1 functions to
promote Tie2 activation. The difference in Tie2 expression and activation between tip cells
and stalk cells can be similarly seen in the difference in Notch signalling. Specifically, Dll4
expressed by tip cells will activate Notch1 on stalk cells to induce a stabilization phenotype
on the stalk cells and preserve differentiation between the two cell types. Consequently, Jag1
expressed by stalk cells antagonize Dll4/Notch signalling. Thus, the balance between Dll4
and Jag1, levels of Notch signalling, and Tie1-Tie2 interactions determine tip and stalk cell
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specificity prevents peri-endothelial cell recruitment and maturation at the angiogenic sprout
(Savant et al., 2015).
In stalk cells undergoing angiogenesis, Ang/Tie2 signalling mediated through paracrine
Ang1 signalling from pericytes inhibits glycogen synthase kinase 3 beta (GSK3B) through
PI3K/Akt activation. This in turn activates Wnt/B-catenin signalling which upregulates
D114/Notch signalling, resulting in deposition of collagen IV to establish the basement layer
of the developing endothelium and ultimately the maturation and quiescence of the newly
developed vasculature (Zhang et al., 2011). Vessel lumen formation and subsequent pericyte
recruitment are necessary for the maturation of the angiogenic process. Epidermal growth
factor-like protein 7 (Egfl-7) is expressed in proliferating tissues and promotes vessel lumen
formation. Conversely, TGFβ inhibits VEGF-mediated vessel lumen formation and prevents
pericyte recruitment. Ang2 promotes the inhibitory actions of TGFβ while Ang1 signalling
can overcome the suppressive effects of TGFβ and promote PI3K mediated tube formation in
the presence of VEGF (Ramsauer et al., 2007; Saito et al., 2003). Lastly, Ang1 signalling
promotes vessel maturation through mural cell recruitment. Endothelial heparin-binding
epidermal-like growth factor (HB-EGF), hepatocyte growth factor (HGF), and PDGF-B have
all been implicated as Ang-induced vSMC and pericyte recruitment factors (Aguilera et al.,
2014; Iivanainen et al., 2003; Kobayashi et al., 2006). Furthermore, pericyte Ang1/Tie2
autocrine signaling assist in mediating endothelial cell-pericyte interactions, and Tie2
deletion in pericytes lead to dysregulated angiogenesis (Teichert et al., 2017). Lastly, both
Ang1 and Ang2 bind to Tie2 with the same affinity. Thus, the delicate balance between
Ang1/Ang2 ratios greatly contributes to determining whether new angiogenic sprouts remain
sprouts or become mature vessels.
As previously mentioned, Ang2 is critical during inflammation as Ang2-deficient mice are
incapable of eliciting an effective inflammatory response (Ulrike. Fiedler et al., 2006). This
is in part due to Ang2-deficient mice’s inability to express endothelial cell adhesion
molecules following TNFα signalling, resulting in impaired endothelial-leukocyte
interactions. This prevents leukocyte infiltration into the damaged tissue. In chronic
inflammation, blood capillaries are remodeled into venules to support vessel leakage and
leukocyte infiltration. Ang2 appears to play a large role in this angiogenic process. In a
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mouse model of chronic airway inflammation, Ang2 inhibition resulted in reduced
remodeling of mucosal capillaries into venules, a reduction in leukocyte emigration, and
decreased disease severity (Tabruyn et al., 2010). Indeed, numerous diseases and cancers
characterized by endothelium activation, increased vascular leakage, and aberrant blood flow
has shown elevated Ang2 concentrations and reduced Ang1 concentration and Tie2
phosphorylation (Fang et al., 2015; Hu et al., 2009; Ong et al., 2010; Yang et al., 2017).
Several anti-Ang2 monoclonal antibodies have been developed for use in anti-angiogenic
therapies in the treatment of solid tumors (Brown et al., 2010). Reduced Ang2 concentrations
have been associated with a better disease prognosis. In models of sepsis, Ang2 heterozygous
mice had reduced vascular leakage and inflammation, and milder kidney and lung injuries
(David et al., 2012). In diabetic retinopathy, Ang2 concentrations have been shown to be
elevated and appeared to mediate pericyte loss and endothelial cell apoptosis (Cai et al.,
2008; Whitehead et al., 2019). In both disease models, administration of COMP-Ang1, an
engineered variant of Ang-1, reduced injury and delayed fibrotic onset. Thus, is it necessary
to evaluate the Ang1/Ang2 ratio in a DMD mouse model and determine the degree of Tie2
activation so that the inflammatory and ischemic microenvironment may be characterized
and addressed.
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Figure 8. Ang/Tie2 signalling in activated endothelium
Ang1/Tie2 signalling enhances endothelial cell migration and proliferation through
phosphoinositide 3-kinase (PI3K) and integrin-mediated activation of the focal adhesion
kinase (FAK) which in turn activates the extracellular signal-regulated protein kinase
(ERK1/2). Tie2 mediated recruitment of Dok-related docking protein (Dok-R) and noncatalytic region of tyrosine kinase adapter protein 2 (NCK2) also contributes to endothelial
cell migration. Vascular permeability increases through decreased mDIa mediated Src
sequestration caused by decreased Ang1/Tie2 signalling, allowing Src to phosphorylate VEcadherin and mediate their internalization. Vascular tube formation via Ang1 signalling
requires VEGF signalling and downstream PI3K signalling. Ang2 can also induce tube
formation through activation of C-Fyn. Ang1/Tie2 signalling facilitates vascular maturation
following the conclusion of angiogenesis through up-regulation of serotonin, heparin-binding
EGF-like growth factor (HB-EGF), and hepatocyte growth factor (HGF), all known to
contribute to smooth muscle cell recruitment. Conversely, elevated Ang2 concentration
results in pericyte dropout. Adapted from Young Koh et al., 2009.
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Ang 1 signalling is also prominent in other cell types (Fig 8). Within the bone marrow,
osteoblasts derived Ang1 induces the adhesion of hematopoietic stem cells (HSCs) to
osteoblasts and helps to maintain a quiescent and anti-apoptotic phenotype within the HSCs
(Arai et al., 2004). Similarly, paracrine and autocrine Ang1/Tie2 signalling in satellite cells
promotes their quiescence and self-renewal through the ERK1/2 pathway resulting in
decreased differentiation and proliferation, entry into G0, and increased activation of antiapoptotic signalling pathways (Abou-Khalil et al., 2009). Ang1 treatment also increased
ESE-1, NERF-2, and ELF-1 transcription factor expression in quiescent satellite cells, all
three of which promote either Ang1 or Tie2 expression, thus, inducing a positive Ang/Tie2
expression feedback loop (Abou-Khalil et al., 2009). Importantly, despite the absence of Tie2
receptors, Ang1 has been found to be capable of binding to myoblasts through N-cadherin
and initiate the expression of myogenin to promote myoblast differentiation and muscle
regeneration (Youn et al., 2018). Lastly, pericytes express functional Tie2 that mediate
downstream signalling of pro-survival and migration pathways through Akt activation and
FOXO3 inhibition (Teichert et al., 2017). However, Tie2 expressing pericyte also appear to
regulate angiogenesis initiation. Sprouting assays of co-culture spheroids of HUVEC and
Tie2-silenced pericytes performed by Teichert et al. showed significant decreases in
endothelial cell sprouting compared to HUVEC cultured with wild-type pericytes (Teichert et
al., 2017). In another experiment, Teichert et al. compared the perfusion and permeability of
tumour vessels in pericyte Tie2 knockout (Tie2PEKO) mice compared to wild type and found
that Tie2PEKO vessels were significantly leakier compared to wild type, revealing the vessel
maturation impact of pericyte Tie2. Taken together, this provides strong evidence that
Ang/Tie2 signalling in pericytes is an important regulator of angiogenesis. Lastly, our lab has
shown that Ang1/Tie2 signalling, independent of other contributing but not crucial factors, is
capable of inducing vessel maturation and stabilization and may hold therapeutic potential in
several diseases that displays immature vascular phenotypes (Gutpell et al., 2017).
Ultimately, without addressing the potential vascular and microenvironment defects, future
curative treatments will not be able to reach their full therapeutic potential.
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Figure 9. Ang1 signalling in myoblast, satellite cells, and pericytes
A) Ang1 interacts with N-cadherin on the surface of myoblasts to induce myogenin
expression via p38MAPK that supports myoblast differentiation and muscle regeneration. B)
Ang1/Tie2 signalling on satellite cells activate the extracellular signal-regulated protein
kinase (ERK1/2) pathway to induce expression of quiescent satellite cell markers Pax7, Myf5, and M-cadherin. C) Ang1/Tie2 signalling in pericytes can directly affect the initiation as
well as the maturation phases of angiogenesis.
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2

Hypothesis and Objectives

2.1 Rationale
Our lab has now shown that localized administration of Ang1 is sufficient in inducing
increased muscle perfusion, reducing inflammation, and reducing the deposition of fibrotic
tissue in hind limb muscle of mdx/utrophin+/- mice. Ang1 is a critical vascular stabilizing
factor that is involved in both maintaining vessel quiescence and angiogenesis maturation.
Any alterations to Ang1/Tie2 signaling mediated by changes in Ang1 concentration or
elevated Ang2 concentrations can lead to hindered angiogenic responses and suboptimal
endogenous muscle repair. It is hence vital to characterize the Ang1/Ang2 ratio in DMD and
determine whether any of the downstream targets of the Ang/Tie2 pathways such as Akt
activation and eNOS phosphorylation are disrupted, so that future therapeutics can be
introduced to correct any abnormalities.

2.2 Hypothesis
We hypothesize that Ang1/Tie2 signalling is dysregulated through elevated Ang2
concentrations in DMD skeletal muscles leading to reduced AKT phosphorylation and eNOS
phosphorylation.

2.3 Specific Aims/ Research Objectives
Aim 1: Characterize the expression of Ang1, Ang2, Tie2, phosphorylated Tie2, and VEPTP
to evaluate changes in Ang1/Ang2 ratio and Tie2 activation in DMD mouse models relative
to normal controls.

Aim

2: Evaluate

changes

in

levels

of

AKT,

phosphorylated-AKT, eNOS,

and

phosphorylated-eNOS to observe select downstream targets associated with Tie2 signalling.
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3

Materials and Methods

3.1 Animal Care and Genotyping
All animal protocols were conducted in strict accordance with the Canadian Council on
Animal Care (CCAC) and were approved by the Animal Use Subcommittee (Western
University, London, ON, Canada). All experiments were performed at The Lawson Health
Research Institute at St. Joseph’s Health Care (SJHC) in London Ontario. C57BL/10 mice
(Jax Laboratories), mdx mice (C57BL/10ScSn-Dmdmdx/J, Jax Laboratories, spontaneous
nonsense mutation), mdx/utrn+/-

(originally generated by Dr.’s Mark Grady and

Josh Sanes (Washington University, St. Louis), were purchased from the Jackson Laboratory
(Bar Harbor, ME) and maintained at the Animal Care Facility at SJHC. Additional wild-type
mice were obtained from Charles River and additional mdx/utrn+/- mice were provided by Dr.
Robert Grange (Virginia Polytechnic and State University). Colonies were maintained under
controlled conditions (19-23˚C, 12-hour light/dark cycles) and allowed water and food ad
libitum. Mice of three age ranges, either 4-5 weeks old, 8-10 weeks old, or 15-20 weeks wild
type, mdx, and mdx/utrn+/- (n=3 for all groups) of either sex were used in this study.
Genotyping was conducted using tail snips or ear notch tissues by polymerase chain reaction
(PCR) with platinum Taq polymerase (Thermofisher), using the following set of utrophin
gene

primers

(Sigma):

5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’,

TGCCAAGTTCTAATTCCATCAGAAGCTG

-3’

(forward

primers)

5’and
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5’-

CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer). Gel electrophoresis was
used to determine the molecular weight of the amplified DNA.

3.2 Tissue Preparation
Mice were sacrificed via gas euthanasia and cervical dislocation upon reaching the desired
age. Diaphragm tissue used for hematoxylin and eosin (H&E) and Masson’s Trichrome
staining were immediately dissected, fixed in 10% formalin for 24-48hrs, and embedded in
paraffin. Section slides were produced from 5µm thick slices taken from every 5 th serial
section. Diaphragm and lung tissues used for western blot, enzyme-linked immunosorbent
assay (ELISA), and qPCR analysis were dissected and immediately flash frozen in dry ice
and stored in -80°C.
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3.3 Microscopy and Image Analysis
Tissue slides were sent to Molecular Pathology at Robarts Research Institute, London, ON,
for H&E and Masson’s Trichrome Staining. Histological images were taken on a Zeiss
Axioskop 50Fluorescence ERGO Trinoc microscope using a 20x objective using Northern
Eclipse Image software. A minimum of five images were taken of each section. Qualitative
analysis assessing the presence of centrally nucleated myofibers and inflammatory infiltrate
(H&E) and collagen (Masson’s Trichrome) was performed as representations of
inflammation and fibrosis in the tissue.

3.4 RNA Extraction and cDNA Preparation
Frozen diaphragm tissue was cut and weighted, producing 10-20mg of tissue. Samples were
subjected to 3 freeze-thaw cycles using liquid nitrogen (LH2), then homogenized in Trizol
Reagent (Ambion), using polypropylene pestles (Fisher Scientific) and an Eppendorf
tube. RNA purification was performed using Direct-zolTM RNA miniprep kit (Zymo) per the
manufacturer’s instructions. An in-solution DNase I treatment was performed postpurification using <10ug of RNA sample, DNase I (Zymo), DNA Digestion Buffer (Zymo),
and water and incubated at room temperature for 15 minutes. Three volumes of Trizol to one
volume of the treated sample were added. RNA purification using Direct-zolTM RNA
miniprep kit was then repeated and suspended in 40ul of RNAase-free water. RNA
concentration and quality were quantified using a DeNovix DS-11 spectrophotometer. All
samples were verified to have a 260/280 ratio above 1.9 and a 260/230 ratio between 2.0-2.2.
cDNA was produced using 1µg of total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) per the manufacturer’s instructions.

3.5 RT-qPCR
Taqman Gene Expression Assays were used to assay Tek (Tie2) (Mm004432343_m1),
Angpt1 (Mm00456503_m1), Angpt2 (Mm00545822_m1), ActB (Mm02619580_g1), AP3D1
(Mm00475961_m1), and GusB (Mm01197698_m1). qPCR products were performed on the
QuantStudioTM 5 system with Taqman Fast Advanced Master Mix (Applied Biosystems).
Quantification was performed using Design & Analysis Software 2.4.3 (Thermofisher). Total

38

Tek, Angpt1, and Angpt2 expressions were normalized to the geometric mean of control
genes: ActB, AP3D1, and GusB.

3.6 Protein Extraction
Tissue were weighed and then homogenized in lysis buffer [20 mM Tris (pH 7.8), 17 mM
NaCl, 2.7 mM KCl, 1mM MgCl2, 1% Triton X-100, 10% (w/v) glycerol, 1mM EDTA,
supplemented with protease inhibitor (Roche) and phosphatase inhibitor (Abcam)] (tissue
weight(mg): lysis buffer volume (µL) = 1:10) and incubated for 4hr at 4°C with continuous
agitation. Samples were then centrifuged at 13 000rpm for 15 minutes and the supernatants
were collected. Total protein was quantified using the bicinchoninic acid assay (Pierce). All
samples were run in duplicates and absorbance was measured at 575nm with an iMarkTM
Microplate Absorbance Reader.

3.7 Western Blot
40µg of protein was combined in 1:1 ratio with Laemmli sample buffer with 2mercaptoethanol, heat denatured at 70°C for 10 minutes, and loaded onto mini-PROTEAN
TGX Stain-FreeTM Precast Gels (Bio-Rad). 15 µl of PageRuler Plus Prestained Protein ladder
was loaded onto the gel. Protein separation vis gel electrophoresis was run at 80 V for 30
minutes followed by 60 minutes at 120 V. The gel was cut and then activated via UV light
using the Bio-Rad Gel Doc system. Protein was transferred onto a PVDF membrane using
the Transblot Turbo machine (Bio-Rad) running for 10 minutes at 1.3 A constant; up to 25 V.
Membrane was blocked with 5% bovine serum albumin (BSA) in tris-buffered saline
containing 0.1% tween 20 (TBS-T) or 5% skim milk in 0.1% TBS-T for 1 hour with constant
agitation. Membranes were incubated with primary anti-Ang1 (Abcam, ab8451, 1:1000),
Ang2 (Invitrogen,

PA5-27297,

1:1000), AKT

(Cell

Signalling,

#9272,

1:2000),

pAKT ser473 (Cell Signalling, #9271S, 1:500), eNOS (Abcam, ab76198), or PhosphoeNOS ser1177 (Mybiosource, MBS9601018, 1:1000) antibodies in 5% BSA TBS-T or 5%
skim milk in 5% TBS-T at 4°C overnight and incubated with anti-rabbit HRP secondary
antibody (Abcam, ab6721, 1:5000) or anti-mouse HRP secondary antibody (Abcam,
ab97023, 1:5000) for 1 hour. Membranes were again thoroughly washed three times for five
minutes with TBS-T. Total protein was visualized and imaged on the Bio-Rad Gel Doc
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system. Chemiluminescent detection was performed using a one-minute incubation with
SuperSignal West Pico PLUS chemiluminescent substrate (ThermoFisher). Bands were
visualized via chemiluminescence using ImageLab (Bio-Rad) on the Bio-Rad Gel Doc.
Signal was normalized to total protein signal from the stain-free blots (Taylor et al. 2013).

3.8 Enzyme-linked Immunosorbent Assay
To quantify levels of Ang1, Ang2, Tie2, and pTie2 in diaphragm tissue lysates, Mouse
Angiopoietin

1

Elisa

Kit

(Develop), Quantikine Mouse

Angiopoietin-2

(R&D

Systems), Quantikine Mouse Tie2 (R&D Systems), Mouse Phosphorylated Tie 2 Duoset IC
Elisa Kit (R&D Systems), and Mouse VE-PTP Elisa Kit (Blue gene) were used. Samples
underwent ½ dilutions and all samples were run in duplicates. Each kit was performed using
the manufacture’s recommended instructions. Samples were measured with an iMarkTM
Microplate Absorbance Reader at 450nm and subtracted by absorbance at 570nm. A standard
curve was generated using the mean absorbance and concentration of each standard in
GraphPad Prism version 8.00 for Windows (GraphPad Software, La Jolla California USA).

3.9 Statistical Analysis
Ordinary one-way ANOVA followed by Tukey’s honest significance test was performed
comparing the difference between groups using GraphPad Prism version 8.00 for Windows
(GraphPad Software, La Jolla California USA). Differences between groups were considered
significant at a p-value of <0.05.
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4

Results

4.1 Ang1/Ang2 ratio is skewed towards Ang2 in mature
mdx/utrn+/- mice relative to age-matched wild-type.
Ang1 and Ang2 both play an important role in mediating Tie2 receptor signalling pathways
and regulating endothelium homeostasis and activation. Due to Ang2 being the competitive
inhibitor of Ang1, the ratio between Ang1 and Ang2 can dictate Tie2 signalling and any
changes in the expression of either protein can lead to a shift in ratio and an alteration in
receptor activation and downstream signalling pathway (Wang et al., 2017). To assess the
expression of Ang1 and Ang2 in diaphragm tissue of 8-10 weeks-old and 15-20 weeks-old
WT, mdx, and mdx/utrn+/- mice, ANGPT1 and ANGPT2 mRNA expression were first
assessed using RT-qPCR. Young (8-10 weeks old) mdx/utrn+/- mice had significantly lower
relative ANGPT1 expression compared to young mdx mice (p=0.0098) and young WT
(p=0.0022). No significant differences in ANGPT2 mRNA expression were observed
between the different genotypes (Fig 9). Interestingly, the subsequent protein data did not
reflect the mRNA data. Using ELISA to quantify protein concentrations, young mdx/utrn+/+
mice (1534.756±518.994 pg/mL) and young mdx/utrn+/- mice (1829.437±1369.454 pg/mL)
had lower Ang1 protein concentration compared to young WT mice (2774.798±1908.568)
but were not significantly different (p=0.3075). In contrast, both young mdx/utrn+/+ mice
(1198.470±300.132 pg/mL)(p=0.0255) and young mdx/utrn+/- mice (1226.882±658.067
pg/mL)(p=0.0123) had significantly higher Ang2 protein concentrations compared to young
WT (346.888±137.783 pg/mL) (Fig 10).
H&E and Masson’s Trichrome staining were performed to validate the inflammatory and
fibrotic nature of the diaphragm tissues respectively. Centrally nucleated myofibers were
visible in young mdx/utrn+/+ and young mdx/utrn+/- diaphragm, indicating the occurrence of
muscle regeneration (Fig 11). Inflammatory infiltrates were present in young mdx/utrn+/- and
young mdx mice. Young and mature mdx/utrn+/- mice diaphragm had profound collagen
deposition, evident of fibrosis. Mature mdx/utrn+/- also displayed collagen deposition,
comparable to mdx/utrn+/- mice (Fig 12).
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In the 15-20 weeks old age group, mature mdx/utrn+/- mice ANGPT1 and ANGPT2 mRNA
expression did not significantly differ relative to mature WT mice. In contrast, mature
mdx/utrn+/+ mice had a significant decrease in ANGPT2 mRNA expression (p=0.013) but not
ANGPT1 mRNA expression) (p=0.9869) relative to the WT mice (Fig 9). However, the
subsequent ELISA protein concentration analysis showed a significant decrease in Ang1
protein concentration in mdx/utrn+/- mice (965.069±473.061 pg/mL)(p=0.0032) compared to
mature WT mice (3163.722±713.035) that was not reflected in the ANGPT1 mRNA
expression data. Additionally, mature mdx/utrn+/- mice did not have a significantly higher
Ang2 protein concentration (1493.863±325.298 pg/mL)(p=0.4078) compared to the mature
WT mice (1101.879±375.764 pg/mL) despite the increase in mRNA concentration (Fig 10).
Mature mdx/utrn+/+ did not have significantly different Ang1 protein concentrations
(2033.553±1023.982

pg/mL)

(p=0.1472)

nor

Ang2

protein

concentrations

(1861.551±761.507 pg/mL) (p=0.1113) compared to the WT.
The changes in Ang1 and Ang2 protein concentrations when analyzed as a function of age
revealed an age-dependent decrease in Ang1 protein concentrations in mdx/utrn+/- in contrast
to an age-dependent increase of Ang1 protein concentrations in both mdx/utrn+/+ and WT
mice (Fig 13). All three genotypes had an age-dependent increase in Ang2 protein
concentrations. Western blot analysis was subsequently performed to confirm the ELISA
data (Fig 14). Upon analysis of relative fold expression ratios between Ang1 and Ang2
mRNA, young mdx/utrn+/- mice had significantly lower ANGPT1/ANGPT2 relative mRNA
expression compared to mdx/utrn+/+ mice (p=0.0398) but not significantly different from
young WT mice (Fig 15). In mature 15-20 weeks-old mice, mdx/utrn+/+ mice had double the
relative Ang1/Ang2 mRNA expression ratios compared to both WT (p=0.0433) and
mdx/utrn+/- (p=0.0452) mice. However, Ang1/Ang2 protein ratio quantification revealed a
significantly lower Ang1/Ang2 ratio in both young (p<0.0001) and mature (p<0.0044)
mdx/utrn+/- mice and young mdx mice (p=0.0027) compared to their WT counterparts (Fig
15). When analyzed as a function of age, the Ang1/Ang2 protein ratio in all three genotypes
decreased as age increased with mdx/utrn+/- mice having the lowest ratio in both age groups.
Altogether, these findings point to a highly skewed Ang1/Ang2 ratio in favour of Ang2
signalling in the skeletal muscle of mdx and mdx/utrn+/- mice that may result in Tie2
inactivation and downstream inhibition.
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Figure 10. Rt-qPCR analysis of Ang1 and Ang2 gene expression.
RT-qPCR analysis of ANGPT1 (Ang1) and ANGPT2 (Ang2) relative fold expression in
young (8-10 weeks-old) and mature (15-20 weeks-old) WT, mdx/utrn+/+, and mdx/utrn+/mice (n=3-5); reference genes: ActB, AP3D1, and GusB. Data are shown as individual
values and mean±s.d. Statistics were performed using one-way ANOVA followed by
Tukey’s Test. *p<0.05, **p<0.01.

43

Ang1 concentration (pg/mL)

✱

8000

8-10 weeks
15-20 weeks

6000
4000
2000
0
mdx/utrn+/+

WT

mdx/utrn+/-

Ang2 concentration (pg/mL)

✱
✱

3000

8-10 weeks
15-20 weeks

2000

1000

0
WT

mdx/utrn+/+

mdx/utrn+/-

Figure 11. ELISA analysis of Ang1 and Ang2 gene expression and protein expression.
ELISA quantification of Ang1 and Ang2 concentration in diaphragm tissues lysates of young
and mature WT, mdx, and mdx/utrn+/- mice (n=3). Data are shown as individual values and
mean±s.d. Statistics were performed using one-way ANOVA followed by Tukey’s Test.
*p<0.05.
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Figure 12. Muscle pathology in 8-10 weeks-old diaphragm muscle of wild-type, mdx,
and mdx/utrn+/-.
Comparison of collagen deposition as an indicator of fibrosis, centrally nucleated myofibers
as an indicator of tissue regeneration, and increased cellularity and polymorphonuclear cells
as an indicator of inflammatory infiltrate.
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Figure 13. Muscle pathology in 15-20 weeks-old diaphragm muscle of wild-type, mdx,
and mdx/utrn+/- mice.
Comparison of collagen deposition as an indicator of fibrosis, centrally nucleated myofibers
as an indicator of tissue regeneration, and increased cellularity and polymorphonuclear cells
as an indicator of inflammatory infiltrate.
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Figure 14. Function of age analysis for Ang1 and Ang2 protein expression.
Visualization of changes in Ang1 and Ang2 protein concentration between diaphragm tissue
of 8-10 weeks of age mice and 15-20 weeks of age mice. Data are shown as mean±s.d.

47

Figure 15. Western Blot Analysis of Ang1 and Ang2.
Representative image of Western blot analysis of Ang1 and Ang2 in diaphragm tissues
lysates of young and mature WT, mdx, and mdx/utrn+/- mice.
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Figure 16. Ang1/Ang2 Ratio Analysis.
Quantification of the ratio of Ang1 relative to Ang2 protein concentration in diaphragm
tissues lysates of young and mature WT, mdx, and mdx/utrn+/- mice (n=3-9). Function of age
analysis for changes in Ang1/Ang2 ratio between 8-10 weeks of age and 15-20 weeks of age.
Data are shown as individual values and mean±s.d. Statistics were performed using one-way
ANOVA followed by Tukey’s Test. *p<0.05, **p<0.01, ****p<0.0001.
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4.2 pTie2/Tie2 ratio is decreased in mature mdx/utrn+/- mice
compared to age-matched wildtype mice
Next, to determine the effects of the change in Ang1/Ang2 ratio on Tie2 expression and
signalling in the diaphragm tissue of of 8-10 weeks-old and 15-20 weeks-old WT, mdx, and
mdx/utrn+/- mice, Tek (Tie2) mRNA was first assessed via RT-qPCR. Neither young 8-10
weeks-old mdx/utrn+/+ mice nor young mdx/utrn+/- mice had significantly different Tie2
mRNA expression relative to young WT mice (p=0.093) (Fig. 16). Protein concentration
analysis via ELISA revealed elevated Tie2 expression in young mdx/utrn+/- mice
(4542.796±613.177 pg/mL), albeit, not significantly higher than WT (3612.270±238.670
pg/mL) or mdx (3802.629± 615.762 pg/mL)(p=0.266). Tie2 mRNA expression in mature 1520 weeks-old mice similarly did not significantly differ between each genotype (p=0.1665).
Tie2 protein concentrations in both mature mdx/utrn+/+ mice (3438.781±2137.56 pg/mL) and
mature mdx/utrn+/- (3230.151±1449.219 pg/mL) were elevated compared to mature WT
(2261.032±1646.605 pg/mL), but were not significant (p=0.6999).
Phosphorylated Tie2 (pTie2) protein analysis via ELISA was then used to evaluate levels of
Tie2 activation and revealed a slight non-significant decrease in pTie2 protein concentration
in young mdx/utrn+/+ mice (1320.922±297.046 pg/mL) and young mdx/utrn+/- mice
(1078.286±388.538 pg/mL) compared to young WT mice (1597.999±532.224 pg/mL).
Similar to the mRNA data, no significant differences in pTie2 protein concentrations was
detected

between

mature

mdx/utrn+/+

(1005.549±619.562

pg/mL),

mdx/utrn+/-

(908.122±477.387 pg/mL), and WT mice (990.652±663.280 pg/mL) (Fig 15). Function of
age analysis showed a similar trend in decreases in both Tie2 and pTie2 concentrations in all
three genotypes (Fig 17).
Interestingly, quantification of the ratio between pTie2 protein concentration and total Tie2
protein concentration showed a significant decrease in pTie2/Tie2 ratio in young mdx/utrn+/mice (0.235±0.065 pTie2/Tie2) and young WT mice (0.437±0.119 pTie2/Tie2)(p=0.0383).
Similarly, this significant difference was seen between mature mdx/utrn+/- (0.259±0.066
pTie2/Tie2) compared to mature WT mice (0.498±0.14 pTie2/Tie2) (p=0.0364). No
significant differences were found between the pTie2/Tie2 ratio of mature mdx/utrn+/+ and
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WT,nor mature mdx/utrn+/- mice (. No significant age dependent changes in ratio were
observed when pTie2/Tie2 ratio was analyzed as a function of time (Fig 18).
To determine whether the changes in pTie2/Tie2 ratio may be due to changes in the Tie2
regulatory protein VE-PTP (Frye et al., 2015), ELISA was performed to determine VE-PTP
protein concentration. No significant differences in VE-PTP protein concentrations were seen
between young mdx/utrn+/+ mice (2100.521±717.907 pg/mL) and young mdx/utrn+/- mice
(2095.981±625.203

pg/mL)

compared

to

young

WT

mice

(1888.470±719.714

pg/mL)(p=0.8486) (Fig 19). Similarly, no significant differences in VE-PTP protein
concentrations were seen between mature mdx/utrn+/+ mice (5593.717±2575.376 pg/mL) and
young mdx/utrn+/- mice (2995±1870.149 pg/mL) compared to young WT mice
(3252.685±1255.981 pg/mL) (p=0.2124), although concentrations were elevated in mature
mice compared to young mice in each genotype. Taken together, this data shows that
severely diseased mature mice have a lower pTie2/Tie2 ratio compared to WT mice.

Tie2 Relative Fold Expression
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Figure 17. RT-qPCR analysis of Tie2 expression and phosphorylated Tie2
concentrations
RT-qPCR analysis of TEK (Tie2) relative fold expression in young (8-10 weeks-old) and
mature (15-20 weeks-old) WT, mdx, and mdx/utrn+/- mice (n=3-4); reference
genes: ActB, AP3D1, and GusB. Data are shown as individual values and mean±s.d. Statistics
were performed using one-way ANOVA followed by Tukey’s test. **p<0.01.
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Figure 18. ELISA analysis of Tie2 expression and phosphorylated Tie2 concentrations.
ELISA quantification of Tie2 and phosphorylated-Tie2 concentration in diaphragm tissues
lysates of young and mature WT, mdx, mdx/utrn+/- mice (n=3). Data are shown as individual
values and mean±s.d. Statistics were performed using one-way ANOVA followed by
Tukey’s test.
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Figure 19. pTie2/Tie2 Ratio Analysis.
Ratio analysis of phosphorylated Tie2 (pTie2) relative to total Tie2 protein concentration
in diaphragm tissues lysates of young and mature WT, mdx, and mdx/utrn+/- mice (n=3). Data
are shown as mean±s.d. Statistics were performed using one-way ANOVA followed by
Tukey’s test. *p<0.05, **p<0.01.
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Figure 20. ELISA analysis of VEPTP expression.
Elisa quantification of VE-PTP protein concentration in young WT, mdx, and mdx/utrn+/mice (n=3-6). Data are shown individual values and mean±s.d. Statistics were performed
using one-way ANOVA followed by Tukey’s test. *p<0.05, **p<0.01.
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4.3 No significant differences in eNOS phosphorylation or Akt
phosphorylation in mdx/utrn+/- mice.
Endothelium homeostasis is partially preserved through Tie2 mediated Akt phosphorylation
leading to eNOS phosphorylation (Babaei et al., 2003). Thus, we wanted to assess whether
the change in pTie2/Tie2 ratio affected Akt phosphorylation and subsequent eNOS
phosphorylation in the diaphragm tissue of 8-10 weeks-old and 15-20 weeks-old WT, mdx,
and mdx/utrn+/- mice. Semi-quantitative western blot analysis normalized to total protein was
used to quantify Akt and eNOS phosphorylation (Fig 20A). In young 8-10 weeks old mice,
phosphorylated Akt protein levels were not significantly different between young
mdx/utrn+/+ mice (0.889±0.376 A.U.), young mdx/utrn+/- mice, and young WT mice.
Phosphorylated Akt levels in the mature 15-20 weeks-old age group similarly did not differ
between mature mdx/utrn+/+, mdx/utrn+/- mice, and mature WTs. The indifference in
phosphorylated Akt levels was reflected in similarly unremarkable phosphorylated eNOS
levels. Phosphorylated eNOS levels remained relatively similar between the disease model
and WT in both young and mature mice (Fig 20B).
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Figure 21. Western Blot analysis of phosphorylated eNOS and pAkt concentration in
diaphragm tissue of WT, mdx, mdx/utrn+/- mice
(A) Representative images of western blot of phosphorylated AKT (Ser473)
and phosphorylated eNOS (Tyr1177) in diaphragm tissues lysates of young and
mature WT, mdx, and mdx/utrn+/- mice. (B) Western blot semi-quantitative analysis of
phosphorylated AKT and phosphorylated eNOS in diaphragm tissues lysates of young and
mature WT, mdx, and mdx/utrn+/- mice; normalized to total protein (n=3). Data are shown
as individual values and mean±s.d. Statistics were performed using one-way ANOVA
followed by Tukey’s Test.
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4.4 Total Akt is upregulated in mature mdx/utrn+/- mice
Although no changes in eNOS phosphorylation nor Akt phosphorylation were observed, total
eNOS and Akt protein levels were also evaluated to rule out any changes in endogenous
protein concentration as a cause for observed results. Western blot analysis was performed
using the same tissue lysates as the eNOS and Akt phosphorylation experiments (Fig 21A).
eNOS levels in the disease model were not significantly different from the WT in either
young or mature mice. Akt protein levels were increased in both young mdx and young
mdx/utrn+/- mice but were not significant. Akt was also elevated in both mature mdx and
mdx/utrn+/- mice, but only mdx/utrn+/- was significant (Fig 21B). This may suggest that the
overall pAkt/Akt ratio is decreased in mature mdx/utrn+/- mice.
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Figure 22. Western blot analysis of total eNOS and Akt protein in diaphragm tissue
lysates
(A) Representative images of western blot of eNOS and Akt in diaphragm tissues lysates of
young and mature WT, mdx, and mdx/utrn+/- mice. (B) Semi-quantitative analysis of total
eNOS and Akt protein in diaphragm tissues lysates of young and mature WT, mdx,
and mdx/utrn+/- mice; normalized to total protein (n=3). Data are shown as individual values
and mean±s.d. Statistics were performed using one-way ANOVA followed by Tukey’s test.
*p<0.05.
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5

Summary, Discussions, Limitations, and Future Directions

5.1 Summary of Results
Vascular therapy for DMD has been predominantly focused on the idea of utilizing VEGF to
stimulate angiogenesis. However, our lab has shown that administration of VEGF alone
cannot correct for the angiogenic defects within DMD, but rather, results in the formation of
leaky vessels that are insufficient for functional perfusion. Subsequent administration of the
vascular stabilizing factor Ang1 in combination with VEGF produced fully mature and
functional vasculature and resulted in marked reductions in inflammation and fibrosis within
the tissue (Gutpell et al., 2017). Ang1/Tie2 signalling in the endothelium is critical for
survival, quiescence, and stability (Brindle et al., 2006; Young Koh et al., 2009). The
importance of Tie2 signalling via Ang1 and Ang2 is perhaps an overlooked area of research
in DMD because of the insufficient characterization data of this signalling pathway in
muscular dystrophies. Thus, the first aim of this study was to characterize Ang1 and Ang2
expression, Tie2 expression and phosphorylation in the dystrophic diaphragm tissue of
mdx/utrn+/+ and mdx/utrn+/- mouse at two timepoints that represented tissue conditions prior
to the onset of fibrosis (8-10 weeks-old) and after fibrosis (15-20 weeks-old). Upon finding
decreased Ang1 expression and increased Ang2 expression that shifted the Ang1/Ang2 ratio
towards Ang2 within the fibrotic mdx/utrn+/- mouse diaphragm, quantification of the
angiopoietin receptor Tie2 was performed. Separately, no significant differences in Tie2
expression nor Tie2 phosphorylation were found. However, upon analysis of pTie2/Tie2
ratios, fibrotic mdx/utrn+/- had a significantly lower pTie/Tie2 ratio relative to the WT.
VEPTP expression was also evaluated and found to be non-significant between groups. This
prompted the question of whether the change in Tie2 activation affected downstream targets
of Tie2 signaling. Thus, aim two of this study was to examine Tie2 downstream Akt and
eNOS expression and phosphorylation. Akt and eNOS were then chosen based on their
contribution to maintaining vascular stability and angiogenesis. Although Akt and eNOS
phosphorylation were not significantly different between the genotypes, total Akt protein
levels were elevated in diaphragm tissue of mature mdx/utrn+/- mice.
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Figure 23. Graphical interpretation of results within mature 15-20 weeks-old
mdx/utrn+/- mice compared to WT mice.
Ang1 protein concentrations were downregulated while Ang2 protein concentrations were
upregulated, resulted in a decreased Ang1/Ang2 ratio. Total Tie2 protein concentration and
pTie2 concentration were not significantly different relative to WT, however, pTie2/Tie2
ratio was significantly lower in the mdx/utrn+/- mice. Phosphorylated Akt, phosphorylated
eNOS, and total eNOS levels were consistent between groups. Total Akt protein levels were
elevated within mdx/utrn+/- mice.

63

5.2 Ang1 protein concentration is decreased in mature
mdx/urn+/- mice
Upon Ang1-mediated activation, Tie2 will undergo auto-phosphorylation (pTie2) and
downstream signal transduction. It is clear that Ang1 plays an important role in mediating
vascular stability and contributes to the positive angiogenic effects of VEGF that are not
observed for VEGF alone, and that impairments in Ang1 may contribute to vascular defects
in DMD including increased vascular permeability and decreased functional perfusion.
However, Ang1 also plays an important role in mediating myogenesis during muscle
regeneration. Injection of COMP-Ang1, a potent derivative of native Ang1, can rescue
ischemic muscle injury and induce muscle fiber regeneration through N-cadherin-mediated
myogenin expression in myoblasts (Youn et al., 2018). Here, in line with our hypothesis of
Ang1 deficiency, we show that Ang1 mRNA and protein concentrations are indeed reduced
in the diaphragm tissue of mature mdx/utrn+/- mice. Downregulation of Ang1 is required for
an effective inflammatory response due to Ang1’s anti-inflammation and vascular stability
effects. However, within the chronically inflamed microenvironment of the dystrophic
diaphragm tissue, Ang1 expression may be insufficient, leading to a persistently de-stabilized
vasculature. Evidence has shown that Ang1’s antileakage action in the context of chronic
inflammation is dependent on the presence of pericytes (Fuxe et al., 2011). Pericytes have
been shown to contribute to muscle regeneration through their differentiation into myoblasts.
Pericytes are also fibro/adipogenic progenitors, capable of differentiating into collagenproducing myofibroblasts that contribute to fibrosis in DMD (Dulauroy et al., 2012).
Depletion of the pericyte population due to their differentiation into other cell types may
directly perturb vascular stability. Ang1 in addition to being constitutively expressed by periendothelial cells such as pericytes and vascular smooth muscle cells is also expressed by
other cells including satellite cells (Abou-Khalil et al., 2009). Satellite cells in DMD are
severely hindered in their ability to self-renew due to impairments in asymmetrical cell
division caused by the lack of dystrophin (Chang et al., 2016; Dumont et al., 2015). The
decrease in Ang1 expression shown in this study may further contribute to a diminished
satellite cell population through reductions in Ang1-mediated satellite cell self-renewal.
Evidence of Ang1 deficiency presented in this study may thus be indirect evidence for
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decreases in both satellite cells and pericytes populations that correlate with cycles of tissue
regeneration and degeneration within the dystrophic skeletal muscles of DMD.
Interestingly, this significant decrease in Ang1 concentration was not seen in the mdx/utrn+/+
diaphragm. Despite the similar levels of fibrosis and regeneration previously reported
between mdx diaphragm and mdx/utrn+/- diaphragm (Gutpell et al., 2015), the difference in
Ang1 expression between the mdx/utrn+/+ and mdx/utrn+/- mice found in this study provides
evidence for pathological differences between the two genotypes that have previously not
been studied. Indeed, one of the major advantages in utilizing the mdx/utrn+/- mouse model
over the traditionally used mdx mouse model is that mdx/utrn+/- mice present clinical
symptoms experienced by DMD patients, compared to the mild pathology seen in
mdx/utrn+/+ mice. Additionally, Ang1 concentrations in both WT and mdx mouse diaphragms
increased over time, whereas it decreased in the mdx/utrn+/- mouse. Again, the expression of
utrophin in mdx mice may assist in its tissue regeneration. Whereas in the mdx/utrn+/-, tissue
regeneration may degrade into pathological regeneration over time that is dominated by
fibrosis and chronic inflammation in the absence of both dystrophin and utrophin. In
situations of inflammation, Ang1 signalling is heavily impeded by the expression of Ang2,
which acts as the competitive antagonist to Ang1.

5.3 Ang2 protein expression is increased in young DMD
murine models
Ang2 is released from the WPB in endothelial cells and act as autocrine signals that compete
with Ang1 for Tie2 binding during the initiation of inflammation. Ang2-mediated inhibition
of Tie2 signaling is necessary for the priming of the endothelial cells to receive inflammatory
signals (Ulrike. Fiedler et al., 2006). The resulting Ang1/Ang2 ratio influences Tie2 receptor
signaling and modulates endothelium quiescence and activation. In several pathological
conditions, severely elevated Ang2 concentrations have been associated with a worse disease
prognosis, often due to aberrant vascular leakage as a function of deficiencies in Tie2
downstream signaling products such as NO (David et al., 2012; Yeo et al., 2008). Given the
observed detrimental effects of impaired Ang2 expression seen in other disease pathologies,
and the importance of Ang1/Ang2 interactions in Tie2 signalling, we sought to evaluate
Ang2 expression within DMD.
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Our results show that in young mice, there were no significant differences in relative Ang2
mRNA expression. However, Ang2 protein concentrations were significantly elevated in
young mdx/utrn+/+ and young mdx/utrn+/- mice relative to the WT. The discrepancy between
the observed mRNA and protein data may be explained by differences in post-transcription
processes and energy abundance (Liu et al., 2016). The initial upregulation of Ang2 protein,
prior to the onset of fibrosis, may help to facilitate the inflammatory response and initiate
angiogenesis within the ischemic tissue, a crucial step in tissue regeneration. In the absence
of Ang2, Tie2-active endothelial cells are unable to elicit an effective inflammatory response
due to the inability to express cell adhesion molecules, thus impairing leukocyte infiltration
(Ulrike. Fiedler et al., 2006; Hughes et al., 2003). Ang2-mediated inactivation of Tie2
indirectly activates NFκβ as well as the transcription factor FOXO1 which upregulates Ang2,
thereby forming a positive feedback loop. This increase in Ang2 protein concentration seen
within mdx/utrn+/- mice also correlates with a proteome profiling analysis of young 4-10year-old human DMD patients which reported elevated Ang2 protein levels in patient serums
(Hathout et al., 2019). Ang2 is also known to be capable of directly mediating endothelial
cell differentiation and sprouting angiogenesis through interactions with integrin β1 on Tie2negative endothelial cells in the presence of VEGF (Hakanpaa et al., 2015). In the absence of
VEGF however, Ang2 induces endothelial cell apoptosis and vessel regression (Ivan et al.,
2002). VEGF expression is downregulated in dystrophic satellite cells (Rhoads et al., 2013).
Additionally, our lab has previously shown that VEGF concentration is significantly
decreased in diaphragm tissue of 9-10 weeks-old mdx/utrn+/- mice (Gutpell et al., 2017).
Thus, a prolonged elevation in Ang2 concentration may contribute to the detrimental
vascular defects in DMD such as vessel regression, rather than supporting regenerating and
inducing angiogenesis. As such, previously demonstrated administration of VEGF may help
initiate angiogenesis and inhibit Ang2-mediated endothelial cell apoptosis and vessel
regression within dystrophic tissue. Additional administration of Ang1 may skew the
Ang1/Ang2 ratio towards Ang1 and allow for Tie2 activation and vessel maturation and
stabilization.
Interestingly, neither of the aged 15-20 week-old mdx/utrn+/+ mice nor the 15-20 week-old
mdx/utrn+/- mice had significantly higher Ang2 concentrations compared to the WT.
Qualitative analysis of H&E and Masson’s Trichrome staining showed that chronic
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inflammation and fibrosis were indeed profound in the diaphragm tissue of mdx/utrn+/- mice
at this age, while similar symptoms present themselves in mdx/utrn+/+ mice diaphragm as
well. Previous serum analysis in Becker muscular dystrophy patients has also associated
elevated Ang2 concentrations with higher degrees of skeletal myopathy (Kaese et al., 2017).
Thus, we had initially hypothesized that Ang2 would be persistently upregulated in the DMD
murine models at this age. When comparing Ang2 protein expression data between the two
age cohorts, all three genotypes had an upwards trend in Ang2 concentration over time.
Therefore, although no significant differences in Ang2 concentration were found in the
mature age group, the level of Ang2 expression was sustained. This sustained increase in
Ang2 coupled with a decrease in Ang1 expression results in an Ang1/Ang2 ratio that may
shift away from Tie2 activation and vascular stability signalling to an inflamed endothelium
phenotype.

5.4 Ang1/Ang2 ratio is skewed towards Ang2 in mature
mdx/utrn+/- mice relative to the age-matched wild-type
Decreased Ang1/Ang2 ratios have been associated with several pathologies including sepsis,
cancer, and metabolic disorders (David et al., 2012; Yeo et al., 2008). This is because the
Ang1/Ang2 ratio can mediate Tie2 activation or inhibition. Thus, the Ang1/Ang2 ratio can be
used as both a prognostic biomarker of endothelial activation and vascular permeability.
However, there is a lack of information regarding Ang1/Ang2 ratio characterization in
degenerative myopathies. To the best of our knowledge, this is the first study to examine the
Ang1/Ang2 ratio in DMD. Here, we show that Ang1/Ang2 protein ratios were significantly
lower in DMD murine models compared to the age-matched WT controls. This change in the
ratio may reflect the inflammatory and ischemic conditions within the skeletal tissue of DMD
mice. The decrease in Ang1/Ang2 ratio, and thus inhibition of Ang1 signalling, is required
for the endothelium to exit from its quiescent state and move into an active state that can
effectively respond to inflammatory and angiogenic signals. However, a chronically
decreased Ang1/Ang2 ratio due to persistent Ang2 signalling and the resultant inability to
return to a quiescent state partly mediated by a high Ang1/Ang2 ratio results in chronically
leaky vasculature that cannot support functional perfusion, leading to tissue ischemia. This
may explain why previous administration of VEGF alone into the similarly fibrotic
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gastrocnemius tissue was unable to induce mature vessel formation. With the subsequent
administration of Ang1, it may have acted to shift the Ang1/Ang2 ratio towards Ang1 and
allow for Ang1-mediated Tie2 activation and the conclusion of the angiogenic cascade.
The shift from a low Ang1/Ang2 ratio to an elevated one is required in angiogenesis for the
maturation of newly formed vessels. It is possible that the persistently low Ang1/Ang2 ratio
in mdx/utrn+/- partially contributes to the reduced functional perfusion and angiogenic defects
seen in its disease pathology. It is interesting to note that Ang1/Ang2 ratio was lower in the
older age group for all genotypes. The decrease in Ang1/Ang2 ratio in mdx/utrn+/- appears to
be mediated primarily by the decrease in Ang1 concentration while changes in mdx/utrn+/+
and WT ratios appear to be due to increased Ang2. The decrease in Ang1 seen in mdx/utrn+/mice may be due to the previously mentioned deficiency in Ang1 expressing cells. The
increase in Ang2 seen in mdx/utrn+/+ and WT mice may be due to increased tissue mass and
vascularization in the mature mice. Protein analysis was done using whole-tissue lysates;
thus, one limitation of this study is the inability to differentiate between Ang2 stored within
Weibel-Palade bodies (WPB) and actively released Ang2. Lastly, Ang2 in physiological
conditions can be a context-dependent Tie2 agonist and antagonist. Evidence has shown that
although Ang2 inhibits Ang1-mediated Tie2 auto-phosphorylation, Ang2 itself can induce
Tie2 phosphorylation and Akt phosphorylation (Yuan et al., 2009). However, in the context
of inflammation, Ang2 signalling in Tie2 is antagonistic. The decrease in the Ang1/Ang2
ratio seen in the dystrophic diaphragm of mdx/utrn+/- mouse may result in Ang2-mediated
Tie2 inhibition and vascular destabilization. Thus, it is necessary to quantify Tie2 and pTie2
levels to verify levels of vascular stability.

5.5 No significant differences in Tie2 expression
Tie2 phosphorylation in the quiescent endothelium helps to promote pro-survival signals
through the downstream expression of survivin and eNOS, anti-inflammation through NFkB
and FOXO1 inhibition, and inter-endothelial cell stability through VE-cadherin
dephosphorylation (Daly et al., 2004; Fukuhara et al., 2010; Gavard et al., 2008; Tadros et
al., 2003; Wong et al., 1997). From the Ang1/Ang2 data, we then hypothesized that pTie2
concentrations would be low relative to total Tie2 concentrations due to Ang2 mediated
inhibition of Tie2 phosphorylation. Here we show that Tie2 mRNA was found to be
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significantly lower in young mdx/utrn+/- mice relative to WT. However, when Tie2 protein
concentration was assessed, mdx/utrn+/- mice had higher Tie2 protein concentration
compared to WT. While Tie2 mRNA is upregulated during wound healing, it has been
reported that Tie2 expression is reduced in conditions relating to severe vascular
complications (Chandra et al., 2016). Tie2, upon Ang1 or Ang2 binding and activation, is
also known to release the ligand, internalize, and then be targeted for degradation. Thus, it is
possible that despite the reduction in Tie2 mRNA expression, Tie2 protein concentration
remains elevated due to a high surface presentation of Tie2 in response to its inhibition by
Ang2. Another factor may be the reduction of VEGF in DMD. Previous studies have shown
that VEGF-induced sprouting angiogenesis is capable of inducing Tie2 cleavage and
downregulating Tie2 mRNA expression in angiogenic endothelial cells (Findley et al., 2007).
The decrease in Tie2 mRNA may be correlated with the level of sprouting angiogenesis
occurring within the tissue of mdx/utrn+/- mice as endogenous muscle repair attempts to
repair the damaged muscle fibers. However, our lab has previously shown a significant
decrease in VEGF protein expression in the diaphragm tissue of 9-10 week-old mdx/utrn+/mice. Therefore, it is also possible that in the absence of high VEGF concentrations, Tie2
ectodomain cleavage does not occur, resulting in higher Tie2 protein presentation. Analysis
of Tie2 mRNA levels and protein expression in mature mice showed similar trends seen in
younger mice. It is also important to note that while Tie2 is most prominently expressed on
endothelial cells, it is also expressed on a variety of other cell types, including satellite cells,
pericytes, macrophages, and fibroblasts. Thus, without being able to isolate endothelial Tie2
expression, changes in Tie2 concentration observed in this study must take into consideration
changes in other cell populations.

5.6 Phosphorylated Tie2 expression and decreased
pTie2/Tie2 ratio in mature mdx/utrn+/- mice
Due to Tie2’s role in maintaining vascular quiescence and stability, Tie2 is constitutively
activated in physiological conditions and inhibited in the context of inflammation. Tie2
phosphorylation is also required for differentiation between tip and stalk cells and vessel
maturation during angiogenesis (Savant et al., 2015). Quantification of pTie2 in young mice
revealed a non-significant decrease in phosphorylated protein concentration within the
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diaphragm tissue of mdx/utrn+/- mice. This decrease did not correlate with the significant
decrease in Ang1/Ang2 ratio shown previously. It is then possible that at 8-10 weeks of age,
Tie2 phosphorylation, vascular stability, and angiogenic capabilities in mdx/utrn+/- mice are
conserved. Young mdx/utrn+/- also demonstrated a slight decrease in mean pTie2
concentration, despite the significant change in Ang1/Ang2 protein concentrations. A
possible explanation in which regenerative capabilities and angiogenesis are functional may
also be applied to mdx/utrn+/+ mice. Interestingly, when looking at pTie2 data in mature mice,
all three genotypes had similar average pTie2 concentrations with large standard deviations.
This variability in concentration was also seen with Tie2 concentration data for the mature
mice. Although initially puzzling, when pTie2/total Tie2 analysis was performed, a
significant trend towards decreased pTie2/Tie2 ratios was observed in mdx/utrn+/- mice
compared to WT. A non-significant decreasing trend was also seen in mdx/utrn+/+ mice. To
eliminate the possibility of the decrease in pTie2/Tie2 ratio due to other inhibitory factors,
VEPTP expression, a prominent endothelial cell-specific receptor tyrosine phosphatase, was
also evaluated. No changes in VEPTP expression were observed between the different
genotypes at 15-20 weeks of age. It is thus unlikely that the observed changed in the
pTie2/Tie2 ratio is due to elevated expression of VEPTP. The decrease in pTie2/Tie2 ratio
seen in the mature mice correlates more similarly with the decrease in Ang1/Ang2 ratio. As
such, the significant decrease in Ang1/Ang2 ratios may result in continuous Ang2 inhibition
of Ang1-mediated Tie2 phosphorylation in the diaphragm tissue of mature mdx/utrn+/+ mice,
leading to vascular instability and angiogenic dysfunction.

5.7 Dysregulated Akt Signalling
The second aim of this project was to evaluate changes in downstream signalling targets of
Tie2 in DMD. One major target that was selected for analysis was Akt. PI3K-mediated Akt
phosphorylation is a major downstream target of Tie2 and is known to contribute to cell
survival, anti-inflammation, and maturation (Shiojima et al., 2002; Somanath et al., 2006).
Elevated Akt is part of physiological muscle regeneration, and several-fold increases in both
pAkt and total Akt protein concentrations in the skeletal muscle of mdx mouse and mdx/utrn/-

mouse, as well as young DMD patient biopsies, have previously been reported (Dogra et

al., 2006). Additionally, conditional Akt overexpression in mdx mice has previously been
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shown to enhance muscle mass and myofiber cross-sectional area (Kim et al., 2011). In this
study, analysis of relative pAkt levels did not reveal any significant differences between WT,
mdx/utrn+/+, and mdx/utrn+/- mice diaphragms. Despite the indifferences in pAkt levels, total
Akt protein expression was higher in mature 15-20 weeks-old mdx/utrn+/- mice diaphragms
compared to the WT. Although Akt phosphorylation and total Akt expression have been
actively cited to be elevated within the skeletal muscles of mdx mouse and DMD patients,
the discrepancy between pAkt and total Akt levels has also been noted (Dogra et al., 2006;
Peter et al., 2006). It has thus been hypothesized that Akt activation in DMD may be
somewhat defective.
Akt signalling in endothelial cells is crucial in both established vasculature as well as vessels
undergoing neovascularization. Studies have been shown Akt signalling to be non-essential
in maintaining endothelial survival in established vessels, but rather, Akt-mediated activation
of Notch signalling regulates the interactions between endothelial cells and mural cells such
as pericytes and vascular smooth muscle cells (Kerr et al., 2016; Si et al., 2020). Specifically,
Akt knockout has been shown to induce pericyte and smooth vascular cell death (Ha et al.,
2019). It is possible then that Akt dysfunction in DMD may result in abnormal mural cell
function or possibly a loss of mural cells. This may be further evidence that the decreased
Ang1 concentration seen earlier may be due to a deficiency in mural cells. In immature
angiogenic cells, however, Akt signalling is vital as it serves to induce an anti-apoptotic
effect, promote VEGF expression, and regulating endothelial cell migration. Indeed,
inhibition of Akt signalling severely attenuates ischemia-mediated blood flow recovery and
angiogenesis (Ackah et al., 2005). As such, the apparent decrease in overall Akt
phosphorylation may be a sign of reduced vascular stability as well as reduced angiogenesis.
Aside from Ang1, several other cytokines such as insulin-like growth factor-1 (IGF-1),
sphingosine-1-phosphate (S1P), reactive oxygen species (ROS), corticosteroids, and VEGF
can activate PI3K mediated Akt signalling as well. Previous studies have implicated a
reduction in autophagy due to altered Akt activation in DMD (De Palma et al., 2012).
Autophagy has been shown to promote angiogenesis. As such, changes in Akt signalling may
directly inhibit angiogenesis through decreased VEGF expression and reduced pro-survival
signalling as well as indirectly inhibiting angiogenesis through Akt-mediated autophagy
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dysfunction. Lastly, Akt signalling is active in myocytes associated with skeletal muscle
growth and muscle regeneration as it regulates the compensatory muscular hypertrophy that
is a hallmark of DMD (Peter et al., 2006). A large limitation of this study is the inability to
delineate Akt expression and activation differences between myocytes and endothelial cells
within the skeletal tissue. Thus, we aimed to analyze an endothelial cell-specific downstream
target of Akt signalling as a means of characterizing Tie2-mediated Akt signaling.

5.8 No Significant Differences in eNOS Expression and
Phosphorylation
One major target of Akt downstream signalling within endothelial cells is Akt mediatedeNOS expression, phosphorylation, and NO production. Previous studies have looked at
eNOS expression in canine models of DMD and found reduced eNOS expression and
reduced cyclic guanosine monophosphate (cGMP) concentrations, leading to increased
vascular leakiness (Dabiré et al., 2011). The observed vascular defect was able to be resolved
directly through the upregulation of eNOS. Indeed, elevations in Ang2 concentrations in
sepsis are inversely proportional to NO-mediated microvascular reactivity (Davis et al.,
2010). Interestingly, our results did not show any significant differences in either eNOS
expression or eNOS phosphorylation between the DMD murine models and WT at neither 810 weeks of age nor 15-20 weeks of age. Ang1 induced beneficial effects have been shown
to be partly mediated via eNOS phosphorylation and NOS production. It has been previously
reported that Ang1 induced angiogenesis relies upon eNOS in vitro, as Ang1 induced
capillary-like tube formation using HUVECs was abolished by the NO inhibitor L-NAME
and eNOS-/- mice exhibited decreased neovascularization upon an Ang1 variant treatment
compared to WT (Babaei et al., 2003). Conversely, Ang1 mediated NO production leads to
increased vascular dilation and maintenance, upregulation of VE-cadherin, and inhibition of
VE-cadherin phosphorylation, all functioning to promote stabilization of the endothelial
barrier. As such, NO within endothelial cells appears to be important in both maintaining
vascular stability as well as angiogenesis initiation. Due to the inflammatory and regenerative
nature of the tissue, it is unlikely that eNOS activation and NO activity in the dystrophic
tissue is strictly vascular maintenance. Rather, it most likely serves to promote the initiation
of angiogenesis within DMD. As such, the indifference in eNOS expression and activation
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may be a sign of dysregulated Akt signalling and dysregulated angiogenesis as eNOS activity
has been positively correlated with ischemic angiogenesis, thus, it should be elevated within
the dystrophic tissues. Causes for eNOS dysfunction may be due to a reduction in upstream
signalling such as a reduction in VEGF, or as shown in this study, a reduction in Ang1
signalling. Thus, taking into account all the results from this study, it is possible that a
significant decrease in Ang1 and increase in Ang2 inhibits Tie2 phosphorylation, thus
altering Akt signalling and reducing eNOS expression and activation within the dystrophic
diaphragm tissue of mature mdx/utrn+/- mice.

5.9 Limitations
This is the first study to use the mdx/utrn+/- mouse model to study the endogenous
Ang1/Ang2 ratios present with the skeletal muscle of DMD. However, there are several
limitations to this study that must be addressed. Firstly, this study only focused on the
diaphragm tissue. It was chosen due to the high contractibility of the muscle and previous
reports of degeneration and fibrosis present in this tissue. However, the hallmark of fibrosis
is the displacement of myofibers and vasculature alike with collagen within the tissue. The
difference in myofiber and vessel density may affect the RT-qPCR and proteomics results,
leading to inaccuracies. As such, it represents a more dystrophic tissue that might not be
representative of other tissues within the host. DMD is a systemic disease, and thus further
serum analysis and other commonly damaged muscles such as the gastrocnemius should also
be evaluated in the future.
Secondly, because the mRNA and protein data were collected from whole tissue lysates, it is
impossible to differentiate the expression between different cell populations. As previously
mentioned, Ang1, Tie2, and Akt are all expressed by several different cell types. As such, we
are unable to differentiate the percentage of total Tie2 protein expressed by pericytes
compared to endothelial cells. Thus, the reported pTie2/Tie2 ratio may not be representative
of the actual ratio present on endothelial cells, resulting in a skewed perception of Tie2
signalling. Additionally, protein analysis of both Ang1 and Ang2 and the ratio between the
two may not directly translate into their availability for Tie2 binding. One reason is due to
the inability of Ang1 to bind to Tie2 as monomers. Instead, oligomerization and
multimerization are required for Ang1-Tie2 binding (Kyung-Tae et al., 2005). However,
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Ang1 monomers are present within the tissue and bind to integrins on myocytes, and promote
pro-survival signalling pathways. Thus, total Ang1 protein analysis may reflect a higher
concentration of Ang1 than is available for Tie2 activation. Another reason is due to Ang2
being stored within WPBs prior to their secretion. Because whole tissue lysate was assessed
rather than serum, we cannot differentiate between secreted Ang2 which is actively able to
bind to Tie2, and Ang2 stored in WPB that cannot contribute to signalling. Thus, Ang2
concentrations may be artificially inflated.
Thirdly, although Akt and eNOS are both major downstream signalling targets involved in
Tie2 activation, they also have several different upstream kinase activators and different
phosphorylation sites. As such, alterations in Akt signalling and eNOS activation reported in
this study cannot be singularly attributed to changes in Tie2 activation. In addition, Protein
analysis of Akt and eNOS, as well as their phosphorylation, were assessed using western
blots. This may introduce inaccuracies due to western blots being only semi-quantitative and
direct comparisons between different blots being unreliable, even if the blots were run in
parallel.
Lastly, this study used both female and male murine models of DMD. DMD is an x-linked
degenerative disease, thus, it typically affects males to a great degree than females. Indeed, at
12 months old, female mdx mice display higher vascular density and increased reperfusion
after ischemic stress compared to their male counterparts (Guéniot et al. 2016). However, no
vascular differences between sex at younger ages have been reported. The usage of a mixedsex cohort is common in mdx mice literature. Due to the low sample size used in this study,
statistical analysis did not factor in sex as a covariant.

5.10 Future Directions
This study, in combination with previous work from our lab, provides further evidence that
Ang1 may be beneficial for vascular therapy in DMD. We have now shown tissue-specific
reductions in Ang1 expression and upregulation in Ang2 expression. This leads to an Ang2skewed Ang1/Ang2 ratio that promotes the inhibition of Tie2 signaling. Without Tie2
activation, vascular stability and angiogenic maturation are hindered. To promote
angiogenesis and support endogenous muscle repair, activation of Ang1-mediated Tie2
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signaling and downstream Akt activation and NO production is required. However, further
investigation is required to determine cell-specific expression profiles. In this regard, future
experiments should pursue the isolation of dystrophic endothelial cells and pericytes and
evaluate Tie2 and Ang2 expression in endothelial cells and Tie2 and Ang1 expression in
pericytes. This will allow us to paint a clearer picture in determining the source of the
changes in the Ang1/Ang2 and pTie2/Tie2 ratios observed in this study. Furthermore,
experiments involving the culturing of dystrophic endothelial cells and pericytes will allow
for greater characterization of these populations within DMD. Evaluation of their angiogenic
capabilities through quantification of Akt and eNOS phosphorylation as well as NO
production in response to angiogenic factors such as Ang1 and VEGF as well as their
response to proinflammatory serum isolated from dystrophic models would provide greater
insight into the vascular defects within DMD. Additionally, we have briefly touched upon the
hypothesis of pericyte deficiencies within DMD being a possible source of decreased Ang1
concentrations due to elevated Ang2 concentrations resulting in pericyte detachment and
pericyte-myofibroblast differentiation. Thus, future experiments should evaluate pericyte
coverage within dystrophic tissues using fluorescence-activated cell sorting or highresolution fluorescence microscopy such as confocal and multiphoton microscopy. To this
end, our lab has begun the investigation of utilizing immunofluorescence (Appendix B),
immunohistochemistry (Appendix C), ex vivo micro-CT (Appendix D), and ex vivo
multiphoton microscopy (Appendix E) to characterize endothelial cell and pericyte specific
expression of Ang1, Ang2, and Tie2 as well as characterizing vasculature density,
vasculature branching, and pericyte coverage in the microvasculature of dystrophic tissue.
Unfortunately, due to health and safety precautions that were implemented in March 2020 in
response to the COVID-19 pandemic, these key experiments, several of which required
intensive inter-disciplinary collaborations, were halted at the proof-of-concept and antibody
selection and validation stages. These experiments will resume following my MSc defence
for publication purposes.
Taken together, characterization of the Ang1/Ang2 ratio and Tie2 activation opens another
avenue of vascular therapy for DMD. Although our lab has shown that increasing Ang1
concentration, and possibly increasing the Ang1/Ang2 ratio may be beneficial in eliciting
mature vasculature formation, it may also be beneficial to investigate anti-Ang2 therapies in
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DMD. In the context of DMD, reducing free Ang2 may shift the Ang1/Ang2 back into an
Ang1-favoured ratio that promotes Tie2 activation, maturation of the angiogenic cascade,
and establishing a stabilized endothelium that can support functional perfusion and
endogenous muscle repair.
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Appendices
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Appendix A: Primer Efficiency Validation.
Validation of primer efficiency for ANGPT1, ANGPT2, Tie2, ActB, AP3D1, and GusB.
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Appendix B: Immunofluorescence stain of endothelial cell marker and pericyte
markers.
Paraffin sections were deparaffinized and rehydrated through a series of xylene and ethanol
washes and ultimately PBS. Antigen retrieval was performed using Retriever 2100 (EMS).
Sections were then rinsed with ddH2O and blocked via incubation with Background Sniper
Blocking Reagent (Biocare Medical) for exactly 8 minutes. Sections were then incubated
with CD31 (Abcam, ab28364, 1:100), CD146 (Abcam, ab75769, 1:100), and αSMA (Abcam,
ab7817, 1:200) in 1% BSA PBS overnight at 4°C. After washes, slides were incubated with
Goat Anti-Mouse (Alexa Fluro 647)(Abcam, ab150115, 1:500) or Donkey Anti-Rabbit
(Alexa Fluro 647)(Abcam, ab150075, 1:500), or Goat Anti-Rabbit (Alexa Fluro 488)(Abcam,
ab150077, 1:500) in 1% BSA PBS for 2 hours at room temperature. Tissue sections were
then washed with PBS, treated with 100ul of Sudan Black for two minutes, and briefly rinsed
with ethanol and PBS. Coverslips were mounted with gold anti-fade with DAPI (Life
Technologies). Nail polish was ultimately used to seal the edges of the coverslip and allowed
to dry for 15 minutes and stored at 4°C.
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Appendix C: Immunohistochemical DAB substrate staining of paraffin-embedded 4week-old WT Lung.
Tissue sections were deparaffinized and rehydrated via a series of xylene and ethanol washes
and then washed with phosphate buffered saline (PBS) prior to antigen retrieval. Antigen
retrieval was performed in citrate buffer with 0.5% Tween at 95°C for 20 minutes and
allowed to cool at room temperature afterward. The citrate buffer was exchanged with PBS
gradually during the cooling process. Tissue sections were placed in 3% H2O2 to inhibit
endogenous peroxidase. Tissue sections were then incubated with Background Sniper
Blocking Reagent (Biocare Medical) for exactly 8 minutes to prevent non-specific antibody
binding. Tissue sections, excluding negative controls, were then incubated overnight at 4°C
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with either Ang-1 (Abcam, ab8451, 1:100), Ang-2 (Invitrogen, PA5-27297, 1:100), Tie2
(Abcam, ab218051, 1:50), phospho-Tie2 (Y992)(R&D Systems, AF2720, 1:100), phosphoeNOS (Ser1177)(MyBioSource, MBS9601018, 1:100), PDGFRβ (Abcam, ab69506, 1:200),
αSMA (Abcam, ab7817, 1:200), and NG2 (Abcam, ab129051, 1:100) in 1% BSA PBS.
Tissue sections were washed with PBS the next day and incubated with biotinylated horse
anti-mouse and biotinylated horse anti-rabbit secondaries for four hours. They were then
incubated in streptavidin for one hour and followed by a DAB substrate kit (Abcam).
Carazzi’s hematoxylin was used to stain the nuclei. Ultimately, they were dehydrated and
coverslip mounted using DAPI Prolong Gold.
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Appendix D: Ex vivo micro-CT with AlumHemFeI stain
Mice were sacrificed via gas euthanasia prior to tissue collection. Diaphragm and
gastrocnemius (GM) muscles from the mice models were dissected and immediately fixed in
formalin for 5 days. Samples were placed in 0.3% Triton X at room temperature for a 24hour soak. Samples were then scanned on the scanner GR eXplore Locus scanner (20um) for
pre-scan images. Samples were then placed into an AlumHemFeI stain or Eribium stain for 5
days and a final scan on GE eXplore Locus scanner (20um).
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Appendix E: Ex vivo Multiphoton Microscopy
50µL of 2-5 µg of Alexa Fluro 647 anti-mouse CD31 (Red)(Biolegend, 102515) and Alexa
Fluro 488 Anti-NG2 (Green)(Sigma-Aldrich, MAB5384A4) were intravenous injected via
the tail vein into mdx mice. The antibodies were allowed to circulate for 15 minutes. Mice
were then euthanized via gas-anesthesia and perfused with 4% paraformaldehyde and flushed
with PBS. The diaphragm was extracted and placed into ice-cold PBS, onto an imaging
apparatus, and imaged.
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